

## CURRICULUM VITAE

Name: M. Roy Wilson, MD, MS

Current Position  
Chancellor  
University of Colorado Denver  
Chairman of the Board, University of Colorado Hospital  
Denver, Colorado

### Education

1976 B.S. Allegheny College  
Meadville, Pennsylvania

1980 M.D. Harvard Medical School  
Boston, Massachusetts

1990 M.S. (Epidemiology) University of California at Los Angeles  
Los Angeles, California

1996 (Certificate,  
Executive Management) Anderson School of Management, UCLA  
Los Angeles, California

1997 (Certificate,  
Executive Development) Marshall School of Business, USC  
Los Angeles, California

### Postdoctoral Training

Internship:  
1980-1981 Internal Medicine  
Harlem Hospital Center  
New York, New York

Residency:  
1981-1984 Ophthalmology  
Massachusetts Eye & Ear Infirmary  
Harvard Medical School  
Boston, Massachusetts

Fellowship:  
1984-1985  
Glaucoma  
Massachusetts Eye & Ear Infirmary  
Harvard Medical School  
Boston, Massachusetts

Licensure and Certification

1981  
Diplomat, National Board of Medicine 226339

1984-2004  
Massachusetts Licensure, No. 52507

1986-Nov. 2005  
California License, No. G57562

1986  
Diplomat, American Board of Ophthalmology

1998-2004  
Nebraska License, No. 20983

2003-2006  
Texas License

2007-  
Colorado License, No. 45762

Academic Appointments

1980-1985  
Clinical Fellow in Ophthalmology  
Harvard Medical School

1985-1986  
Clinical Assistant in Ophthalmology  
Harvard Medical School  
Boston, Massachusetts

1985-1986  
Clinical Instructor  
Department of Surgery  
Division of Ophthalmology  
Howard University School of Medicine  
Washington, D.C.

1986-1990  
Assistant Professor and Chief  
Division of Ophthalmology  
Charles R. Drew University of Medicine and Science  
Los Angeles, California

1986-1991  
Assistant Professor  
Department of Ophthalmology  
University of California, Los Angeles  
Los Angeles, California

1990-1994  
Associate Professor and Chief  
Division of Ophthalmology  
Charles R. Drew University of Medicine and Science  
Los Angeles, California

1991-1994	Associate Professor Department of Ophthalmology University of California, Los Angeles Los Angeles, California
1993-1995	Academic Dean College of Medicine Charles R. Drew University of Medicine and Science Los Angeles, California
1994-1998	Professor Charles R. Drew University of Medicine and Science Los Angeles, California
1994-1998	Professor Department of Ophthalmology University of California, Los Angeles Los Angeles, California
1995-1998	Dean College of Medicine Charles R. Drew University of Medicine and Science Los Angeles, California
1997-1998	Associate Dean School of Medicine University of California, Los Angeles Los Angeles, California
1998-2003	Dean Professor of Ophthalmology School of Medicine Creighton University Omaha, Nebraska
1999- 2001	Interim Vice President for Health Sciences Creighton University Omaha, Nebraska
2001-2003	Vice President for Health Sciences Creighton University Omaha, Nebraska
2003-2006	President, Texas Tech University Health Sciences Center Professor of Ophthalmology Lubbock, Texas
2006-	Chancellor Professor of Ophthalmology University of Colorado Denver Denver, Colorado

Hospital Appointments

1985-1986	Assistant in Ophthalmology Massachusetts Eye and Ear Infirmary Boston, Massachusetts
1985-1986	Consultant Ophthalmologist Victoria Hospital Castries, St. Lucia
1986-1998	University of California, Los Angeles Los Angeles, California
1986-1998	Chief Physician King/Drew Medical Center Los Angeles, California
1998-2003	Saint Joseph Hospital Omaha, Nebraska
2003-2006	University Medical Center Lubbock, Texas
2007-	University of Colorado Hospital Denver, Colorado

Other Appointments

1985-1986	Project Director International Eye Foundation Ministry of Health Castries, St. Lucia
-----------	---

Awards and Honors

1973	Alden Scholar
1974	Alden Scholar
1975	Alden Scholar
1976	Alden Scholar
1976	Phi Beta Kappa
1976	Magna Cum Laude
1976	Department Honors in Biology
1976	Senior Thesis Award
1993	Honor Award, American Academy of Ophthalmology
1994	Massachusetts Eye and Ear Infirmary Honored Alumnus Award
1995	Distinguished Physician Award, Minority Health Institute

1996	Best Doctors in America multiple consecutive year listing since 1996 including current
2000	Alpha Omega Alpha, Faculty Member
2001	Top Cat Award, Nebraska Chapter of American Academy of Pediatrics
2002	Dr. Stan Truelsen Award, Prevent Blindness Nebraska
2002	Roman Barnes Society of Ophthalmology, 2 <sup>nd</sup> Annual Award
2003	Admiral, Great Navy of the State of Nebraska
2003	Senior Achievement Award, American Academy of Ophthalmology
2003	Gold Citation, Allegheny College
2004	Headliner Award, Women in Communications
2007	Herbert W. Nickens Award, American Association of Medical Colleges
2008	Golden Key International Honor Society, Honorary Member

#### Professional Societies

1979-1985	Massachusetts Medical Society
1979-	American Medical Association
1980-	Harvard Medical Alumni Association
1981-1984	National Association of Interns & Residents
1983-1989	Trabecular Meshwork Study Club
1984-	Association for Research in Vision and Ophthalmology
1984-	Chandler-Grant Glaucoma Society
1985-	National Medical Association
1985-	American Academy of Ophthalmology
1985-1990	Society of Eye Surgeons International Eye Foundation
1985-	Massachusetts Eye and Ear Infirmary Alumni Association
1986-1998	Southern California Glaucoma Society
1986-1998	West Coast Glaucoma Study Club
1986-1993	Association of University Professors in Ophthalmology
1987-	UCLA Department of Ophthalmology Alumni Association
1988-1998	Los Angeles County Medical Association

1988-1998	Los Angeles Society of Ophthalmology
1988-1998	California Medical Association
1989-	American Glaucoma Society
1992-2000	Society for Epidemiologic Research
1992-2000	American Public Health Association
1997-2000	American College of Epidemiology
1998-2003	Metro Omaha Medical Society (Executive Committee)
1998-2003	Omaha Ophthalmologic Society
1999-2003	Nebraska Academy of Ophthalmology
1999-2005	Association for Academic Minority Physicians
1998-2005	Pan American Association of Ophthalmology
2002-	American Ophthalmological Society (by invitation and acceptance of thesis)
2003-	International Glaucoma Research Society (by invitation, membership limited to 75 worldwide)
2003-	Institute of Medicine, National Academy of Sciences (by invitation)
2003-2006	Texas Medical Association
2003-2006	Academy of Medicine, Engineering, and Science of Texas (by invitation)

**School Activities (prior to July 1998 only)**

1986-1990	Operating Room Committee King/Drew Medical Center
1986-1994	Program Directors Committee King/Drew Medical Center
1986-1994	Department of Surgery Executive Committee King/Drew Medical Center
1986-1994	Clinical Appointments and Promotions Committee Department of Ophthalmology University of California, Los Angeles

- 1987-1988 Chairman, Search Committee for  
Department of Internal Medicine Chairperson  
Charles R. Drew University of Medicine and Science
- 1987-1994 Member, Grievance Committee  
Charles R. Drew University of Medicine and Science
- 1987-1994 Advisory Board for International Health  
Department of International Health  
Charles R. Drew University of Medicine and Science
- 1987-1990 Associate Member, Jules Stein Eye Institute Committee
- 1989-1994 Director, Ophthalmic Epidemiology and Clinical Research Unit  
Charles R. Drew University of Medicine and Science
- 1990-1998 Founding Chairman, Epidemiology and Clinical Vision  
Research Study Group  
Jules Stein Eye Institute, UCLA
- 1990-1998 Member, Jules Stein Eye Institute Committee
- 1990 (March) Jules Stein Eye Institute  
Teaching Course: Current Concepts for Glaucoma  
Management: Medical, Laser and Surgical XXVI  
International Congress of Ophthalmology, Singapore
- 1990 (April) Moderator, Laser Section of 21st  
JSEI Annual Postgraduate Seminar: Glaucoma: Current  
Concepts in Diagnosis and Management
- 1990 (September) Faculty, Combined Jules Stein/MLK  
Postgraduate Laser Course and Workshop
- 1991-1992 Chairman, Laser Committee  
King/Drew Medical Center
- 1991-1993 International Health Research Committee  
Department of International Health  
Charles R. Drew University of Medicine and Science
- 1991 (February) Course Co-Director, 1st Annual Doheny/JSEI Practical  
Epidemiology and Biostatistics for Ophthalmologists
- 1991 (September) Faculty, JSEI Postgraduate Laser Course and Workshop
- 1992 (January) Course Co-Director, 2nd Annual JSEI/Doheny Practical  
Epidemiology and Biostatistics for Ophthalmologists
- 1992 (September) Faculty, JSEI Postgraduate Laser Course and Workshop

1993-1994	Secretary-Treasurer, Professional Staff Association King/Drew Medical Center
1993-1998	Founding Director, Center for Eye Epidemiology Jules Stein Eye Institute, UCLA
1993-1995	Director, Jules Stein Eye Institute Glaucoma Fellowship Selection Committee
1993-1995	Glaucoma Faculty Search Committee Jules Stein Eye Institute, UCLA
1993 (December)	Course Director Practical Epidemiology and Biostatistics for Ophthalmologists Jules Stein Eye Institute, UCLA
1994-1998	Executive Committee Charles R. Drew University
1994-1998	Research Executive Committee Charles R. Drew University
1994-1996	Advisory Committee Research Centers for Minority Institutions
1994 (December)	Course Director Practical Epidemiology and Biostatistics for Ophthalmologists Jules Stein Eye Institute, UCLA
1995-1997	Glaucoma Division Chief Search Committee
1995 (April)	Course Co-Director 25th Annual Jules Stein Eye Institute Postgraduate Seminar
1995 (September)	Faculty, Jules Stein/Drew Postgraduate Laser Course and Workshop
1995 (December)	Course Director Practical Epidemiology and Biostatistics for Ophthalmologists Jules Stein Eye Institute, UCLA
1997 (February)	Course Director Practical Epidemiology and Biostatistics for Ophthalmologists Jules Stein Eye Institute, UCLA
1997	Clinical Scholars Program Policy Advisory Committee UCLA School of Medicine
1998 (February)	Course Co-Director What You Need to Know About Quality of Life and Outcomes Studies Jules Stein Eye Institute, UCLA

Advisories/Consultantships:

1987-1990	International Eye Foundation Bethesda, Maryland
1989-1996	Great Hands Advisory Board Beaver Instruments Becton Davidson
1990-1994	National Scientific Advisory Board for Diabetes 2000 American Academy of Ophthalmology
1990-1996	Research and Development Committee Singapore Association of the Visually Handicapped
1990-1997	Faculty Advisory Board Merck, Sharpe and Dohme
1992-1995	Glaucoma 2001 Subcommittee on Risk Factors
1992-2000	National Scientific Advisory Board for Glaucoma 2001 American Academy of Ophthalmology
1993-2005	Glaucoma Advisory Committee Prevent Blindness America
1993-1998	Glaucoma Detection Subcommittee Prevent Blindness America
1993-1996	Advisory Committee to the Baltimore Eye Survey Follow-up Study
1993-2001	American Health Assistance Foundation, National Glaucoma Research Scientific Review Committee
1993-	Scientific Advisory Board of Glaucoma Foundation (New York)
1995-1999	FDA Advisory Committee, Dermatologic and Ophthalmic Drugs
1995-2002	Scientific Advisory Committee, Glaucoma Research Foundation (San Francisco)
1995-1996	Honorary Advisory Board, Eyeville
2000-	EyeCare America, Glaucoma Project American Academy of Ophthalmology
2000-2001	National Research Council, Committee on Disability Determination for Individuals with Visual Impairments
2000-2002	Advisory Committee, Office of Minority Health, NIH

2001-2002	Howard University: Research Centers in Minority Institutes (RCMI) National Advisory Committee
2001-	FDA Advisory Committee, Ophthalmic Devices Panel
2002-2005	Advisory Council, National Center on Minority Health and Health Disparities, NIH
2002-2003	Institute of Medicine, Committee on Roles of Academic Health Centers in the 21 <sup>st</sup> Century
2002	NSF Advisory Panel, Survey of Scientific and Engineering Research Facilities, National Science Foundation
2002-2003	Xalatan Cultural Advisory Board, Pharmacia
2002-2003	Ocular Hypertension Treatment Study Advisory Board, Pharmacia
2002-2005	Pharmacia/Pfizer Ophthalmics, Glaucoma Risk Initiative Faculty
2003-2007	Pfizer Ophthalmics, Glaucoma Advisory Board
2003-2005	Chair, Strategic Plan Subcommittee National Center on Minority Health and Health Disparities, NIH
2003-2006	Health-Related Institutions Formula Advisory Committee Texas Higher Education Coordinating Board
2003	Allergan Glaucoma Advisory Council
2004-2006	Allergan Health Outcomes Advisory Board
2004-2006	Advisory Board, Achievement Rewards for College Scientists
2005-2006	Co-chair, Expert panel Rand Method for Assessing Glaucoma Therapy Insyght (unrestricted grant from Pfizer Ophthalmics)
2005-	Advisory Board, Undergraduate Medical Academy Texas
2006	Advisory Board, Road to Health 2006 Tavis Smiley's Health, Fitness, and Wellness Expo
2006-	National Advisory Research Resources Council of the National Institutes of Health
2006-	Advisory Board, World Glaucoma Association

2006- National Center on Minority Health and Health Disparities  
Society of Fellows and Scholars, Charter Class

Governing Board Memberships:

1998-2001	Boys and Girls Club of Omaha Omaha, Nebraska
1998-2003	Saint Joseph Hospital Omaha, Nebraska
1998-2003	Children's Hospital Omaha, Nebraska
1998-2003	Children's Physicians Omaha, Nebraska
1998-2003	Glaucoma Foundation New York, New York
1998-2003	UniNet Healthcare Network Omaha, Nebraska (Treasurer)
1998-2003	Creighton – Nebraska Universities Health Foundation (President, 2001- 2002)
1998-2003	Creighton Medical Associates (Chair)
2001-2003	Creighton University-BoysTown Healthcare Foundation (Treasurer)
2002-2003	International Latin American Concern Santiago, Dominican Republic
2003-2005	Prevent Blindness Texas Texas
2003-2005	Reese Redevelopment Authority Board Lubbock, Texas
2004-2006	United Way Lubbock, Texas
2006-	Chairman of the Board, University of Colorado Hospital Aurora, Colorado
2006-	The Children's Hospital Aurora, Colorado

2006- Auraria Higher Education Center  
Denver, Colorado

2006- Fitzsimons Redevelopment Authority,  
Aurora, Colorado

2007- Institute of International Education  
Rocky Mountain Region

2007- Delta Eta Boule Foundation  
Denver, Colorado

2007- Colorado Biosciences Association  
Denver, Colorado

Review Activities:

1990 (October) Special Review Committee SRC-O2  
National Eye Institute, NIH

1991 (March) Ad Hoc Reviewer Visual Sciences A2 Study Section  
National Eye Institute, NIH

1991 (November) Committee Member, Ad Hoc Site Visit  
National Institute on Aging, NIH

1992-1996 NIH Section Member, Vision Research Review Committee  
National Eye Institute, NIH

1992- Reviewer, Peer Review Journals  
Journal of Glaucoma  
Ophthalmology  
Investigative Ophthalmology and Visual Science  
American Journal of Ophthalmology  
Journal of American Medical Association  
Archives of Ophthalmology  
Survey of Ophthalmology  
British Journal of Ophthalmology

1992 (October) Grant Review, British Columbia  
Health Research Foundation

1992 (November) Committee Member, Ad Hoc Grant Review  
National Institute on Aging, NIH

1993 (January) Special Review Committee for Foreign Grant Application  
National Eye Institute, NIH

1993 (March) Special Review Committee for Foreign Grant Application  
National Eye Institute, NIH



- 1991 (April) Moderator, Clinical Research:  
Glaucoma/Vision Research Section  
Association for Research in Vision and Ophthalmology
- 1991 (June) Faculty, Lancaster Course in Ophthalmology
- 1991 (November) Glaucoma Faculty for Project Orbis  
Yangon, Myanmar (Burma)
- 1992-1995 Member, ARVO Committee on Women and Minorities  
Association for Research in Vision and Ophthalmology
- 1992 (January) Mini-course on Epidemiology and Biostatistics  
New York Eye and Ear Infirmary, New York, New York
- 1993-1994 Public Health Committee  
American Academy of Ophthalmology
- 1993-1996 Nominating Committee, American Glaucoma Society
- 1993 (November) Moderator  
American Academy of Ophthalmology/  
National Society to Prevent Blindness  
1993 Glaucoma Symposium  
Glaucoma: The Common Pathway to Blindness
- 1994- Executive/Steering Committee, NEI Ocular Hypertension  
Treatment Study Clinical Trial
- 1994-1995 Chairman, ARVO Task Force on Minority Issues  
Association for Research in Vision and Ophthalmology
- 1994-2000 Basic and Clinical Science Course Committee  
American Academy of Ophthalmology
- 1994-1997 Nominating Committee  
Prevent Blindness America
- 1994 (May) Moderator, Normal-tension Glaucoma/Ocular Blood Flow  
Association for Research in Vision and Ophthalmology
- 1994 (July) Visiting Professor  
King Khaled Eye Specialist Hospital  
Riyadh, Saudi Arabia
- 1994 (September) Co-director, Epidemiology Course  
Beijing, China
- 1995-1998 Glaucoma Outcomes Committee  
American Academy of Ophthalmology

1995 (January)	Visiting Faculty, Orbis International Caribbean Regional Glaucoma Symposium Kingston, Jamaica
1995 (May)	Moderator, Glaucoma-New Ideas Association for Research in Vision and Ophthalmology
1995 (October)	Glaucoma Basic and Clinical Science Course: Essentials of Glaucoma, What You Need to Know American Academy of Ophthalmology Course 125
1996 (April)	Moderator, Epidemiology and Sociology in Glaucoma Association for Research in Vision and Ophthalmology
1996-1998	Member, Los Angeles County Medical Association (LACMA) Task Force on Public/Private Relationships
1996-1998	Executive Committee, Los Angeles Society of Ophthalmology
1997-1998	Program Chairman, Los Angeles Society of Ophthalmology
1997 (May)	Moderator, Glaucoma Clinical Research I Association for Research in Vision and Ophthalmology
1998 (May)	Moderator, Glaucoma Clinical Pharmacology I Association for Research in Vision and Ophthalmology
1998 (November)	Glaucoma Basic and Clinical Science Course: Essentials of Glaucoma American Academy of Ophthalmology Course 640
1999	Selection Committee, Outstanding Community Services Award AAMC
1999-	Associate Examiner, American Board of Ophthalmology
2000-2005	Selection Committee, Herbert Nickens Minority Medical Student Scholarships, AAMC
2000 (August)	Co-Director, International Ophthalmology Pre-Convention Scientific Symposia, National Medical Association
2000-2003	Committee Member, Women's Health Initiative Council of Nebraska
2000 (October)	Current Controversies in Glaucoma American Academy of Ophthalmology Course 237
2000 (October)	How To Critically Interpret Research Results and to Translate These Results into Clinical Care American Academy of Ophthalmology Course 465
2001, 2002	Spring Meeting Planning Committee Council of Deans, AAMC

- 2001 (February) Moderator, Oral Presentations  
American Glaucoma Society
- 2001 (March) Chairman, Epidemiology/Genetics Section  
3rd International Glaucoma Symposium  
Prague, Czech Republic
- 2001 (July) Moderator, Update in the Management of Glaucoma  
Co-Instructor, Pitfalls and Pearls in the Use of Drainage Devices  
XXIII Pan American Congress of Ophthalmology  
Buenos Aires, Argentina
- 2001-2003 Committee Member, Nebraska EPSCOR  
(Experimental Program to Stimulate Competitive Research)
- 2001 (September) Moderator, Professional Clinical Chairs Workshop on Minority  
Faculty Development  
Case Western Reserve/University Hospitals Health System  
Cleveland, Ohio
- 2001 (October) Moderator, Meeting Health Challenges of Emerging Populations  
of Color  
Health and Human Services, Office of Minority Health and  
Human Services  
Omaha, Nebraska
- 2001 (November) How to Critically Interpret Research Results and to Translate  
These Results into Clinical Care  
American Academy of Ophthalmology Course 116
- 2002 Nomination Committee, Association of Academic Health  
Centers
- 2002 (June) Round Table Discussant, Non-Penetrating Glaucoma Surgeries  
35<sup>th</sup> Panhellenic Ophthalmological Congress  
Chalkidiki, Greece
- 2002 (August) Panel Discussant, National Medical Association 2002 Annual  
Convention and Scientific Assembly  
Honolulu, Hawaii
- 2002 (October) Discussant, Meet the Experts-Fellows Program  
OHTS: Implications for Clinical Practice  
Orlando, Florida
- 2003 (March) Moderator, Glaucoma Epidemiology and Genetics  
4<sup>th</sup> International Glaucoma Symposium  
Barcelona, Spain
- 2003 (November) Moderator, AAO Glaucoma Subspecialty Day  
Epidemiology and Global Perspective  
Anaheim, California

- 2003 (November) Discussion chair, 1<sup>st</sup> Global AIGS Consensus Meeting on Structure and Function in the Management of Glaucoma: Evidence Based Diagnosis  
San Diego, California
- 2004- Task Force, Financial Barriers to Health Care in Texas
- 2004 Co-chair, American Heart Association Heart Walk
- 2004 (October) Roundtable Discussant, Frontiers in Glaucoma  
New Orleans, Louisiana
- 2004- Co-chair, Association of International Glaucoma Society's Committee on Global Research and Screening of Glaucoma
- 2005-2006 Interim (Founding) Chair, Health Disparities Education, Awareness, Research, and Training Consortium (HDEART)  
President's Council
- 2005 Moderator, AAO Glaucoma Subspecialty Day  
Which Ocular Hypertensive Patient Should Be Treated?  
Chicago, Illinois
- 2006 Deputy Director Search Committee, National Center on Minority Health and Health Disparities, NIH
- 2006 Association of Academic Health Centers Membership Committee
- 2006 (October) Moderator, AAO Glaucoma Subspecialty Day.  
Glaucoma: the Ophthalmologist's Dilemma.  
Las Vegas, Nevada
- Discussant, AAO Editor's Choice Symposium.  
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma.  
Las Vegas, Nevada
- 2007 (March) Moderator, IGS Session  
Epidemiology and Geographical Glaucoma.  
Athens, Greece
- 2007 (July) Chair, Didactic Session  
World Glaucoma Congress  
The Association of International Glaucoma Societies  
Singapore
- 2007 (July) Chair, Course 30  
World Glaucoma Congress  
The Association of International Glaucoma Societies  
Singapore

2008 (April) 5<sup>th</sup> WGA Global Consensus Meeting for Screening Open Angle  
Glaucoma, Angle Closure and Angle Closure Glaucoma  
Consensus Development Participant

Grants (P.I. unless otherwise stated)

1984	National Research Service Award Source: National Eye Institute Amount: \$18,000
1985	Glaucoma Prevalence Study Source: Agency for International Development Amount: \$100,000 (Direct cost only) Total Project Cost: \$400,000 (Estimated)
1986	Mitomycin for Pterygium Therapy Source: Biomedical Research Support Grant/Charles R. Drew University of Medicine and Science Amount: \$1,505
1986	An Evaluation of the Acceptance and Ease of Use of a Reminder Cap in Subjects Using a Tropical Medication Two Times a Day Source: Allergan Pharmaceuticals Amount: \$2,250
1987	A Clinical Evaluation of the Safety and Efficacy of Ofloxacin vs. Tobramycin External Ocular Infections Source: Allergan Pharmaceuticals Amount: \$4,500
1988	Levobunolol vs. Dipivefrin as the Initial Treatment of Black Glaucoma Patients Source: Allergan Pharmaceuticals Amount: \$20,000
1988	Mitomycin and Filters Source: Biomedical Research Support Grant/Charles R. Drew University of Medicine and Science Amount: \$2,000
1989	A Phase II Multiple-Dose Study of Abbott-64662 Ophthalmic Solution Administered Three Times-A-Day to Patients With Elevated Intraocular Source: Abbott Laboratories Amount: \$29,550
1991	Eye Injury Research Source: Southern California Injury Prevention Research Center Amount: \$10,000

- 1991                      Blindness and Visual Impairment in Cameroon, West Africa  
Source:                  Agency for International Development  
Amount:                 \$100,000 (Direct cost only)  
Total Project Cost:     \$700,000 (Estimated)
- 1992                      Evaluation of Metipranolol/Pilocarpine Ocular Drops in Treating  
Open Angle Glaucoma and Ocular Hypertension  
Source:                  Bausch and Lomb Pharmaceuticals  
Amount:                 \$55,625
- 1993                      Ocular Hypertension Treatment Study (OHTS) Clinical Center  
Source:                  National Eye Institute, NIH  
Amount:                 \$738,286 (5 years)
- 1994                      Population Based Study of Functional Visual Impairment in  
South-East Los Angeles (Co-investigator)  
Source:                  Research Centers for Minority Institutions  
Amount:                 \$60,000/Yr for 4 Years
- 1994                      Depression and Glaucoma  
Source:                  Research to Prevent Blindness  
Amount:                 \$20,000
- 1994                      Health Related Quality of Life in Glaucoma Patients  
(Co-principal investigator)  
Source:                  Glaucoma Research Foundation  
Amount:                 Approximately \$100,000
- 1995                      A Randomized, Double-Masked, Multicenter, Parallel Study  
Comparing The Effects of Carteolol and Timolol  
Ophthalmic Solution  
Source:                  Otsuka America Pharmaceutical  
Amount:                 \$31,824
- 1995-1997                Ocular Hypertension Treatment Study  
Ancillary Study: Heidelberg Retinal Tomography  
Clinical Center  
Source:                  National Eye Institute, NIH  
Amount:                 \$74,000
- 1996                      Cataract Management Trial: Visual Function and Costs  
(Co-Investigator)  
Source:                  Claude D. Pepper Geriatric Research and  
Training Center, NIH  
Amount:                 \$656,505 (5 years)
- 1997                      \*Research Centers for Minority Institutions, Core Infrastructure  
Development Grant  
Source:                  NIH  
Amount:                 \$4,257,080 (5 years)

1997 Ocular Hypertension Treatment Study  
Ancillary Study: Heidelberg Retinal Tomography Clinical  
Center (Co-PI)  
Source: National Eye Institute, NIH  
Amount: Approx. \$14,000/yr (5 years)

1997 \*Clinical Trials Unit (Drew)  
Source: NIH  
Amount: \$7,931,717 (6 years)

1997 Center for Eye Epidemiology (JSEI, UCLA)  
Source: Ahmanson Foundation  
Amount: \$1,000,000 (one time gift)

1999 \*Pipeline to Success at Creighton  
Source: Department of Health and Human Services  
(HRSA)  
Amount: \$1,285,105 (3 years)

1999 \*Health Professions Partnership Initiative  
Source: Robert Wood Johnson Foundation  
Amount: \$347,243 (5 years)

2001 Thessaloniki Eye Study  
Source: International Glaucoma Association  
Amount: \$50,000

2002-2003 Thessaloniki Eye Study  
Source: Health Future Foundation  
Amount \$47, 870

2002 \*CO6 RR 17417-01  
Source: National Centers for Research Resources, NIH  
Amount: \$2,000,000

2003 \*Center of Excellence (Creighton)  
Source: Department of Health and Human Services  
(HRSA)  
Amount: \$1,692,153 (3 years)

2004 Thessaloniki Eye Study  
Source: Texas Tech University Health Sciences Center  
Amount: \$25,000

\* PI of institutional grants

Invited Presentations

1. *Epidemiology of Glaucoma*. National Medical Association Conference, Dallas, Texas. July 1980.
2. *Effect of Race on Open-Angle Glaucoma*. Joint Annual Meeting of the Massachusetts Eye and Ear Infirmary Alumni Association and New England Ophthalmological Society, Boston, Massachusetts. April 1984.
3. *Glaucoma in Blacks*. National Medical Association Conference. July 1984.
4. *Glaucoma Epidemiology*. Glaucoma Update Course Massachusetts Eye and Ear Infirmary, Harvard Medical School, Department of Continuing Education, Boston, Massachusetts. March 1985.
5. *Diagnostic Dilemmas In Angle Closure Glaucoma*. National Medical Association Conference, New Orleans, Louisiana. August 1987.
6. *Diagnosis and Treatment of Patients With Narrow Angles*. Cedars-Sinai Ophthalmology Staff Continuing Education, Los Angeles, California. October 1987.
7. *National Survey of the Prevalence of Glaucoma in St. Lucia, West Indies*. 12th Annual UCLA Department of Ophthalmology Association Clinical Conference, Los Angeles, California. December 1987.
8. *Blood Induced Glaucomas*. Grand Rounds Jules Stein Eye Institute, Los Angeles, California. March 1988.
9. *Special Considerations of Glaucoma in Blacks*. National Medical Association, Los Angeles, California. August 1988.
10. *Glaucoma and Trauma*. Fifth Annual Bangkok Ophthalmology Meeting, Bangkok, Thailand. January 1989.
11. *Post-Surgical Glaucomas*. Fifth Annual Bangkok Ophthalmology Meeting, Bangkok, Thailand. January 1989.
12. *Racial Differences in Therapeutic Responsiveness to Glaucoma Agents*. The Second Caribbean Glaucoma Symposium, St. Thomas, Virgin Islands. March 1989.
13. *Narrow Angle Glaucoma: Pearls and Pitfalls*. The Second Caribbean Glaucoma Symposium, St. Thomas, Virgin Islands. March 1989.
14. *Glaucoma After Cataract Surgery*. National University Hospital, Singapore. January 1990.
15. *Epidemiology and Treatment of Narrow Angles*. National University Hospital, Singapore. January 1990.
16. *Changing Views on Angle-Closure Glaucoma*. Western Regional Update Course American Academy of Ophthalmology, Irvine, California. February 1990.
17. *Practical Classification of the Glaucomas (Gonioscopy)*. Western Regional Update Course American Academy of Ophthalmology, Irvine, California. February 1990.

18. *Why Do People Go Blind From Glaucoma?* New England Ophthalmology Society W. Morton Grant Festschrift, Boston, Massachusetts. March 1990.
19. *Epidemiology of Glaucoma.* XXVI International Congress of Ophthalmology, Singapore. March 1990.
20. *Epidemiology of Glaucoma.* 21st JSEI Annual Postgraduate Seminar, Los Angeles, California. April 1990.
21. *Performing Gonioscopy and Diagramming Angles.* Cedars-Sinai Ophthalmology Staff Continuing Education Program, Los Angeles, California. July 1990.
22. *Angle Closure Glaucoma.* Memorial Hospital Medical Center of Long Beach Continuing Education Program, Long Beach, California. November 1990.
23. *What Do We Know About Glaucoma Risk Factors?* Research Study Club of Los Angeles, Los Angeles, California. February 1991.
24. *What Does Epidemiology Have To Do With Ophthalmology?* 1st Annual Doheny/JSEI Practical Epidemiology and Biostatistics for Ophthalmologists, Los Angeles, California. February 1991.
25. *Diabetes 2000.* NEI, National Eye Health Education Program, Hilton Head, South Carolina. February 1991.
26. *Prognostic Factors in Glaucoma Filtering Surgery.* 22nd JSEI Annual Postgraduate Seminar, Los Angeles, California. March 1991.
27. *Glaucoma Filtration Surgery: Pearls and Perils.* National Medical Association Conference, Indianapolis, Indiana. July 1991.
28. *Risk Assessment in Glaucoma.* International Glaucoma Symposium, Jerusalem, Israel. August 1991.
29. *Is IOP the Cause of Glaucoma?* Beilinson Medical Center, Tel Aviv, Israel. August 1991.
30. *Risks in Glaucoma Surgery.* Update Course in Ophthalmology (Curso de Actualizacion Oftalmologica), Los Angeles, California. October 1991.
31. *Glaucoma in the Diabetic Patient: Pathophysiology.* Diabetes 2000 Symposium American Academy of Ophthalmology Meeting, Anaheim, California. October 1991.
32. *Epidemiology and Pathophysiology of Narrow Angles and Angle Closure Glaucoma.* National Hospital Yangon Myanmar. November 1991.
33. *A Critical Look at Glaucoma Risk Factors.* Grand Rounds JSEI, Los Angeles, California. January 1992.
34. *POAG: Epidemiology and Risk Factors.* Visiting Professor University of California at San Francisco, San Francisco, California. May 1992.
35. *Prevalence and Incidence of Glaucoma: Who Has It and Who Gets It?* Current Ophthalmic Practice Symposium, Jules Stein Eye Institute, Los Angeles, California. June 1992.

36. *Prevalence and Incidence of Glaucoma: Who Has It and Who Gets It?* 1992 Summer Institute American Academy of Ophthalmology, San Francisco, California. July 1992.
37. *Eliminating Preventable Blindness From Diabetes by the Year 2000.* Diabetes Complications Symposium, National Medical Association Conference, San Francisco, California. August 1992.
38. *Neovascular Glaucoma: Pathophysiology and Management.* National Medical Association Conference, San Francisco, California. August 1992
39. *Glaucoma After Trauma.* California Association of Ophthalmology, 11th Annual Educational Conference, Dana Point, California. September 1992.
40. *Blebs: Prognostic Factors for Survival and Influencing Its Function.* Xth International Congress of Eye Research, Stresa, Italy. September 1992.
41. *Epidemiology of Open Angle Glaucoma.* Conference at Morehouse School of Medicine, Glaucoma in the Afro-American: The Forgotten Majority, Atlanta, Georgia. January 1993.
42. *Neovascular Glaucomas.* Conference at Morehouse School of Medicine, Glaucoma in the Afro-American: The Forgotten Majority, Atlanta, Georgia. January 1993.
43. *New Concepts in Neovascularization.* Grand Rounds, JSEI, Los Angeles, California. February 1993.
44. *Mitomycin C in Glaucoma Filtration Surgery: Who, How, Why, and Why Not.* Research Study Club of Los Angeles, 62nd Annual Mid-Winter Clinical Conference, Los Angeles, California. February 1993.
45. *Racial Considerations in the Diagnosis and Management of Glaucoma.* The Fourth Caribbean Glaucoma Symposium, St. Thomas, Virgin Islands. March 1993.
46. *Short Update on Mitomycin.* Medical Staff Meeting, JSEI, Los Angeles, California. March 1993.
47. *Risk Factors for Glaucoma: Fact or Fiction?* Visiting Professor, University of California at San Diego, San Diego, California. April 1993.
48. *Screening for Diabetic Retinopathy: The Primary Care Physician's Role.* "Academics at Midway" CME Program, Midway Hospital Medical Center, Los Angeles, California. April 1993.
49. *Practical Tips on Using Mitomycin-C.* Current Ophthalmic Practice Seminar, Mercy Health Care Hospital, Bakersfield, California. May 1993.
50. *Antimetabolites in Glaucoma Filtration Surgery.* National Medical Association Conference, San Antonio, Texas. August 1993.
51. *Update on Diabetes 2000.* Pre-Convention Diabetes Symposium, National Medical Association, San Antonio, Texas. August 1993.
52. *Optimizing Surgical and Laser Therapy in Glaucoma.* Glaucoma in the Developing World Symposium, Montego Bay, Jamaica. September 1993.

53. *Prevalence and Causes of Blindness in the Extreme North Province of Cameroon.* Cameroon, West Africa. November 1993.
54. *Update on the Use of Antimetabolites in Filtration Surgery.* Glaucoma Update 1993 Conference, University of California, Irvine, California. December 1993.
55. *IOP: Evolving Concepts and Its Influence on the Management of Glaucoma.* Grand Rounds, JSEI, Los Angeles, California. February 1994.
56. *Sturge Weber Syndrome.* 24th JSEI Annual Postgraduate Seminar, Los Angeles, California. April 1994.
57. *What All Primary Care Eye Providers Must Know About Glaucoma?* Ocular Symposium: Pearls in Ocular Diagnosis, Universal City, California. May 1994.
58. *Glaucoma Implant Surgery.* Grand Rounds, Riyadh, Saudi Arabia. July 1994.
59. *Repairing Leaking Blebs.* Grand Rounds, Riyadh, Saudi Arabia. July 1994.
60. *Recent Advances in Risk Factor Research.* Research Conference, Riyadh, Saudi Arabia. July 1994.
61. *Glaucoma Filtration Surgery: Pearls and Pitfalls.* University Eye Hospital, Colombo, Sri Lanka. August 1994.
62. *Another Perspective on Intraocular Pressure.* New England Ophthalmological Society/Massachusetts Eye and Ear Alumni Scientific Meeting, Boston, Massachusetts. October 1994.
63. *Risk Factors for Glaucoma.* Pre-Academy Glaucoma Symposium, San Francisco, California. October 1994.
64. *Demographics of Glaucoma:Focusing on the High Risk Groups.* American Academy of Ophthalmology/National Society to Prevent Blindness Glaucoma Symposium, San Francisco, California. October 1994.
65. *Discussion of Paper: Racial Differences in Optic Nerve Head Topography.* American Academy of Ophthalmology, San Francisco, California. October 1994.
66. *Clinical Trials and Longitudinal Studies: How They Are Influencing Glaucoma Management.* 25th JSEI Annual Postgraduate Seminar, Los Angeles, California. April 1995.
67. *Nuts and Bolts of Glaucoma Evaluation.* Ocular Symposium, Universal City, California. April 1995.
68. *Antimetabolites in Glaucoma Filtration Surgery.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.
69. *Review of Glaucoma Implants: Principles and Practices.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.
70. *The Ahmed Glaucoma Valve Implant: The UCLA Experience.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.

71. *Update on Assessing Optic Nerve Head Topography.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.
72. *Current Trends in Glaucoma Management.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.
73. *Epidemiological Features of Glaucoma.* Third Annual International Ophthalmology Conference, Cali, Colombia. May 1995.
74. *Review of Glaucoma Implants: Principles and Practices.* Current Ophthalmic Practice Seminar, Cottage Hospital, Santa Barbara, California. June 1995.
75. *Confocal Laser Imaging of the Optic Nerve Head.* Current Ophthalmic Practice Seminar, Cottage Hospital, Santa Barbara, California. June 1995.
76. *Low Tension Glaucoma: Another Perspective.* International Symposium on Modern Challenges of Ophthalmology and Visual Sciences, Hong Kong. July 1995.
77. *Practical Tips on Performing Glaucoma Implant Surgery.* Shanghai Second Medical School, Shanghai, China. July 1995.
78. *The Ahmed Glaucoma Valve Implant: Theory, Indications, Technique, and Clinical Experience.* University of Indonesia, Jakarta, Indonesia. July 1995.
79. *Comparison of Currently Available Glaucoma Drainage Implants.* National Medical Association Conference, Atlanta, Georgia. August 1995.
80. *Glaucoma Implants.* Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Colombo, Colombo, Sri Lanka. August 1995.
81. *Low Tension Glaucoma.* Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Colombo, Colombo, Sri Lanka. August 1995.
82. *Interpreting Automated Perimetry.* Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Colombo, Colombo, Sri Lanka. August 1995.
83. *Nuts and Bolts of Glaucoma Evaluation: Gonioscopy, Optic Nerve Assessment, and Visual Fields.* National Optometric Association, Southern California Chapter, Monterey Park, California. September 1995.
84. *Update on the Ocular Hypertension Treatment Study.* National Optometric Association, Southern California Chapter, Monterey Park, California. September 1995.
85. *Discussion of Paper: Routine Eye Care is Essential for Preventing Blinding Eye Disease.* American Academy of Ophthalmology, Atlanta, Georgia. October 1995.
86. *Low Tension Glaucoma.* Research Study Club, Los Angeles, California. February 1996.
87. *Clinical Trials: How They Have Influenced Glaucoma Management.* Research Study Club, Los Angeles, California. February 1996.

88. *Glaucoma in the Caribbean*. Ophthalmological Society of West Indies, Barbados, West Indies. July 1996.
89. *Glaucoma Screening and Control Strategies*. Ophthalmological Society of West Indies, Barbados, West Indies. July 1996.
90. *A Perspective on Intraocular Pressure and Glaucoma*. National Medical Association Conference, Chicago, Illinois. July 1996.
91. *Clinical Trials: Value and Impact*. American Academy of Ophthalmology/Prevent Blindness Glaucoma Symposium, Chicago, Illinois. October 1996.
92. *Newer Techniques in Glaucoma Management: Glaucoma Drainage Devices*. All India Ophthalmology Society Conference, New Delhi, India. February 1997.
93. *Glaucoma Clinical Trials: Their impact on How We Currently Manage Glaucoma*. All India Ophthalmology Society Conference, New Delhi, India. February 1997.
94. *Practical Tips on Glaucoma Management*. All India Institute of Medical Sciences, New Delhi, India. February 1997.
95. *Glaucoma Clinical Trials: How They Influence How We Practice*. Society of Air Force Clinical Surgeons, 44th Annual Symposium, Sacramento, California. April 1997.
96. *Argon Laser Trabeculoplasty*. Lasers in Ophthalmology Course, Jules Stein Eye Institute UCLA, Los Angeles, California. September 1997.
97. *Laser Peripheral Iridotomy*. Lasers in Ophthalmology Course, Jules Stein Eye Institute UCLA, Los Angeles, California. September 1997.
98. *What Causes Glaucoma?* Ahmedabad Academy of Ophthalmology, Ahmedabad, India. September 1997.
99. *Glaucoma Clinical Trials Update*. Ahmedabad Academy of Ophthalmology, Ahmedabad, India. September 1997.
100. *The Meat and Potatoes of Epidemiology*. American Glaucoma Society, Mini-Symposium, Scottsdale, Arizona. December 1997.
101. *Depression and Quality of Life in Glaucoma Patients*. National Glaucoma Research Symposium, American Health Assistance Foundation, 25th Anniversary Program, San Diego, California. January 1998.
102. *Normal Tension Glaucoma: IOP as a Causative Factor*. Glaucoma Symposium, 28th International Congress of Ophthalmology, Amsterdam, The Netherlands. June 1998.
103. *Health Status and Quality of Life Measures*. Visiting Professor, University of Maryland, Baltimore, Maryland. July 1998.
104. *Update of Quality of Life in Glaucoma Patients*. National Medical Association Conference, New Orleans, Louisiana. August 1998.

105. *Early Diagnosis is Unimportant.* Subspecialty Day, American Academy of Ophthalmology, New Orleans, Louisiana. November 1998.
106. *Clinical Trial of Trabeculectomy versus Ahmed Implant.* American Glaucoma Society, Amelia Island, Florida. February 1999.
107. *Health-Related Quality of Life in Cataract and Glaucoma.* Omaha Ophthalmological Society, Omaha, Nebraska. March 1999.
108. *Epidemiology of Glaucoma.* Harvard School of Public Health, Boston, Massachusetts. March 1999.
109. *Consideration of Glaucoma Surgery from a Worldwide Perspective.* Jules Stein Eye Institute Postgraduate Seminar, Los Angeles, California. April 1999.
110. *Natural History of Glaucoma.* Jules Stein Eye Institute Postgraduate Seminar, Los Angeles, California. April 1999.
111. *Diversity in Health Science Education.* University of Nebraska Medical Center, Omaha, Nebraska. May 1999.
112. *Minority Physicians: What Are Our Obligations?* Harvard Medical Alumni Association, Boston, Massachusetts. June 1999.
113. *The Natural History of Glaucoma: Implications of the St. Lucia Follow-up Study.* The 2<sup>nd</sup> Congress of Ophthalmology, University of San Paulo, San Paulo, Brazil. November 1999.
114. *Quality of Life In Glaucoma and Cataract.* The 2<sup>nd</sup> Congress of Ophthalmology, University of San Paulo, San Paulo, Brazil. November 1999.
115. *Trabeculectomy versus Ahmed Implant Clinical Trial Results.* The 2<sup>nd</sup> Congress of Ophthalmology, University of San Paulo, San Paulo, Brazil. November 1999.
116. *Perspective on Glaucoma Screening.* The 2<sup>nd</sup> Congress of Ophthalmology, University of San Paulo, San Paulo, Brazil. November 1999.
117. *Clinical Trial Update.* The 2<sup>nd</sup> Congress of Ophthalmology, University of San Paulo, San Paulo, Brazil. November 1999.
118. *Who Should Be Screened For Glaucoma and How Should It Be Done?* The Links, Incorporated, Philadelphia, Pennsylvania. December 1999.
119. *Introduction to Mission Based Management.* Association of Medical School Pediatric Department Chairs. Annual Meeting, San Diego, California. March 2000.
120. *Normal Tension Glaucoma.* Italian Association for the Study of Glaucoma, Rapallo, Italy. March 2000.
121. *Incidence of Glaucoma and Progression of Glaucoma.* University of Colorado 4<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. March 2000.

122. *Clinical Trial of Trabeculectomy vs Ahmed Implant: Long Term Results.* University of Colorado 4<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. March 2000.
123. *Health Related Quality of Life: Implications for Glaucoma.* University of Colorado 4<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. March 2000.
124. *Decision Making – Indications for Combined Surgery.* East Coast Glaucoma Symposium, New York, New York. May 2000.
125. *How Should I Screen for Glaucoma?* East Coast Glaucoma Symposium, New York, New York. May 2000.
126. *From St. Lucia to The Cameroons: Infrastructure Needs for Research and Clinical Care.* National Medical Association, Washington DC. August 2000.
127. *Screening for Glaucoma in High Risk Populations.* Congressional Glaucoma Caucus Foundation, Washington DC. August 2000.
128. *Is IOP Merely a Risk Factor for Glaucomatous Injury or an Intrinsic Part of the Disease?* Glaucoma 2000 Subspecialty Day, American Academy of Ophthalmology, Dallas, Texas. October 2000.
129. *St. Lucia Follow-up Study: The Natural History of Glaucoma.* American Glaucoma Society, Newport Beach, California. February 2001.
130. *Achieving Better Health for All Americans.* Nebraska Alzheimer Association and the Center for Aging, Alzheimer and Neurodegenerative Diseases, Omaha, Nebraska. August 2001.
131. *Racial Differences in Prevalence of Eye Diseases: Now What?* University of Colorado 5<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. September 2001.
132. *How Fast Do Visual Fields Progress in Treated and Untreated Eye?* University of Colorado 5<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. September 2001.
133. *Strategies for Glaucoma Screening: One Size Does Not Fit All.* University of Colorado 5<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. September 2001.
134. *What Have We Learned from the Normal Tension Glaucoma Treatment Trial?* University of Colorado 5<sup>th</sup> Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
135. *When Should Glaucoma Drainage Implants Be Used?* University of Colorado 5<sup>th</sup> Annual Ophthalmology Symposium, Denver, Colorado. September 2001.
136. *Making Opportunities Available for Students of Diverse Backgrounds.* Keynote Speaker, Northeastern Ohio Universities College of Medicine, Akron, Ohio. October 2001.
137. *Should Treatment of Glaucoma In Blacks Differ?* Glaucoma 2001 Subspecialty Day, American Academy of Ophthalmology, New Orleans, Louisiana. November 2001.
138. *Societal Burden of Glaucoma.* American Academy of Ophthalmology/Prevent Blindness, America Glaucoma Symposium, New Orleans, Louisiana. November 2001.

139. *Worldwide Implications of the Challenges of Health Care Delivery in Glaucoma.* American Academy of Ophthalmology/Prevent Blindness, America Glaucoma Symposium, New Orleans, Louisiana. November 2001.
140. *Glaucoma: What You Don't Know Could Blind You.* Keynote Speaker: Glaucoma Awareness Month Kick-off Event, St. Joseph Hospital, Omaha, Nebraska. January 2002.
141. *Visual Field Progression in Glaucoma – How Often and How Fast!* 35<sup>th</sup> Panhellenic Ophthalmological Congress, Halkidiki, Greece. June 2002.
142. *Glaucoma in the Caribbean: Implications for Glaucoma in African Americans.* National Medical Association 2002 Annual Convention and Scientific Assembly, Honolulu, Hawaii. August 2002.
143. *Race and Glaucoma: Beyond Prevalence.* National Medical Association 2002 Annual Convention and Scientific Assembly, Honolulu, Hawaii. August 2002.
144. *Quality of Life and Therapy: Is it Worth Treating?* Commemoration of the 20<sup>th</sup> Anniversary of the Baltimore Eye Survey, Baltimore, Maryland. September 2002.
145. *OHTS: Implications for Clinical Practice?* Glaucoma 2002 Subspecialty Day, American Academy of Ophthalmology, Orlando, Florida. October 2002.
146. *Recent Advances in Glaucoma: Results of the Ocular Hypertension Treatment Study.* Orlando, Florida. October 2002.
147. *OHTS: Do I Need to Treat Everybody?* New York Society for Clinical Ophthalmology, Winter Meeting, New York, New York. December 2002.
148. *Normal Tension Glaucoma: History and Epidemiology.* 4<sup>th</sup> Japan Glaucoma Council, Tokyo, Japan. December 2002.
149. *Evidence Based Medicine: Role of the Reviewer,* Glaucoma Specialists Consultants Meeting, New York, New York. December 2002.
150. *Lessons Learned from Glaucoma Epidemiological Studies and Application to Clinical Practice.* Glaucoma Symposium, Thessaloniki, Greece. January 2003.
151. *OHTS: From the Results to Clinical Practice.* Glaucoma Symposium, Thessaloniki, Greece. January 2003.
152. *OHTS Risk Factors.* OH: Defining Risk & Clinical Options, Las Vegas, Nevada. January 2003.
153. *Epidemiology and Risk Factors for Glaucoma and Glaucoma Blindness.* Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute, Cleveland, Ohio. March 2003.
154. *A Perspective on Race and Glaucoma.* Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute, Cleveland, Ohio. March 2003.
155. *Should Glaucoma Drainage Implants Be Used for Initial Surgery of Uncomplicated Glaucoma?* Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute, Cleveland, Ohio. March 2003.

156. *Evidence Based Medicine: A New Approach to Glaucoma*. American Glaucoma Society 2003 Annual Meeting, San Francisco, California. March 2003.
157. *Multi Center Clinical Studies: Clinical Implications of OHTS*. 4<sup>th</sup> International Glaucoma Symposium, Barcelona, Spain. April 2003.
158. *Randomized Controlled Trials of Therapy in Glaucoma. The Glaucoma Laser Trial*. Glaucoma Society of the International Congress of Ophthalmology, Chantilly, France. May 2003.
159. *Randomized Controlled Trials of Therapy in Glaucoma. Global Perspectives on RCTS – A North American View*. Glaucoma Society of the International Congress of Ophthalmology, Chantilly, France. May 2003.
160. *Pipeline to Success at Creighton University: Pathways to Increased Student Retention*. National Association of Medical Minority Educators, Inc., Kansas City, Missouri. September 2003.
161. *Academic Health Science Center's Role in Economic Development of the Community*. Downtown Chapter of the American Business Club, Lubbock, Texas. November 2003.
162. *An Argument for Switching Rather than Adding Glaucoma Medication*. Bascom Palmer Eye Institute Glaucoma Mid-Winter Symposium, Coral Gables, Florida. January 2004.
163. *Every mmHg Reduction is Important in the Treatment of Glaucoma*. Bascom Palmer Eye Institute Glaucoma Mid-Winter Symposium, Coral Gables, Florida. January 2004.
164. *A Call to Action for Better Health for our Community*. Keynote Speaker, Mt. Vernon United Methodist Church, Lubbock, Texas. February 2004.
165. *Health Disparities from Cancer in West Texas*. Texas Cancer Council, Austin, Texas. February 2004.
166. *Leadership in Medicine*. Alpha Omega Alpha, Lubbock, Texas. April 2004.
167. *Lessons Learned from Glaucoma Epidemiological Studies and Application to Clinical Practice*. Beijing International Glaucoma Conference, Beijing, China. April 2004.
168. *Lighting the Path to Preeminence*. Texas Tech University Health Sciences Center Symposium, Lubbock, Texas. April 2004.
169. *Strategies for Glaucoma Screening*. Update on Therapeutic Treatments for Glaucoma, Chicago, Illinois. May 2004.
170. *Does 1 mmHG of Pressure Lowering Matter?* Update on Therapeutic Treatments for Glaucoma, Chicago, Illinois. May 2004.
171. *Switching vs. Adding Medication*. Update on Therapeutic Treatments for Glaucoma, Chicago, Illinois. May 2004.
172. *Collaborative Normal-Tension Glaucoma Trial*. Update on Therapeutic Treatments for Glaucoma, Chicago, Illinois. May 2004.

173. *Health Care: Ensuring Better Access, Benefits, Choices, and Healthy Lifestyles.* African American Leadership Summit, Washington DC. May 2004.
174. *Projecting Progression Rates in Glaucoma.* 7<sup>th</sup> Congress of the European Glaucoma Society, Florence, Italy. May 2004.
175. *Toward a Bi-national Cooperation for Medical Education.* Border Health Forum, Juarez, Mexico. June 2004.
176. *Disparities in Health in America: Working Toward Social Justice.* 2004 Summer Health Disparities Workshop, The Center for Research on Minority Health at University of Texas M.D. Anderson Cancer Center, Houston, Texas. June 2004.
177. *The Glaucoma Continuum.* Boston, Massachusetts. July 2004.
178. *Cameroon Eye Study.* Third Annual Research Day, Texas Tech University School of Pharmacy, Amarillo, Texas. July 2004.
179. *Applying Evidence-based Medicine (EBM) in Everyday Ophthalmic Practice.* Boston, Massachusetts. August 2004.
180. *Global Risk Assessment of Multiple Risk Factors.* Boston, Massachusetts. August 2004.
181. *Translating Risk into Clinical Practice: What is the Threshold for Therapy?* Glaucoma 2004 Subspecialty Day, American Academy of Ophthalmology, New Orleans, Louisiana. October 2004.
182. *Global Glaucoma Perspective-Epidemiology.* Glaucoma Specialists Forum, Las Colinas, Texas. November 2004.
183. *All Is Not Well: Improving the Health of the Community.* Community Baptist Church, Lubbock, Texas. February 2005.
184. *Racial and Ethnic Disparities in Diseases and Outcomes.* Update for the Comprehensive Ophthalmologist Meeting, Lubbock, Texas. June 2005.
185. *Value-Based Medicine.* Association of International Glaucoma Societies World Glaucoma Congress, Vienna, Austria. July 2005.
186. *Ethnicity-Race. Considering Population-based Studies in Different Populations.* From Research to Clinical Practice: Thessaloniki Eye Study- First Results, Aristotle University of Thessaloniki Department of Ophthalmology, Thessaloniki, Greece. September 2005.
187. *Clinical Trials: Special Challenges and Opportunities Related to Minority Populations.* 2005 Annual Meeting, Association of Academic Health Centers, Ponte Vedra Beach, FL. September 2005.
188. *Treatment of Risk in the Glaucoma Continuum: The Glaucoma Continuum,* Miami, FL. November 2005.
189. *Glaucoma and You.* Coalition of African American Churches. Dallas, TX. February 2006.
190. *A Vision in Glaucoma.* Black Faculty/Staff Association Health Fair. Lubbock, TX. February 2006.

191. *Glaucoma: Landmark Clinical Trials and Their Impact on Practice*. 13th International Glaucoma Congress, Athens, Greece. March 2006.
192. *Risk Calculation and Glaucoma Management in the “Glaucoma Continuum.”* 39th Panhellenic Ophthalmological Congress, Thessaloniki, Greece. June 2006.
193. *Empowering Communities Through Committed Service*. Guest speaker for the Lubbock Alumnae Chapter of Delta Sigma Theta’s “Man and Woman of the Year Community Service Award” program, Lubbock, TX. June 2006.
194. *Identification and Screening—Background*. Glaucoma Society, International Congress of Ophthalmology, Vancouver, Canada. June, 2006.
195. *Pharmacologic Treatment Worldwide Issues—Pharmacogenetics and Ethnicity*. Glaucoma Society, International Congress of Ophthalmology, Vancouver, Canada. June, 2006.
196. *Searching for Diversity: Conducting Successful Searches*. Association of American Medical Colleges 2006 Annual Meeting, Seattle, WA. October, 2006.
197. *Young Scholars and the Importance of Mentoring*. Keynote Lecture. Colorado Conference of Minority Transportation Officials 2<sup>nd</sup> Annual Scholarship Banquet. Denver, CO. March, 2007.
198. *Medical Education and the Public Trust*, Plenary Session. Western Group on Student Affairs Spring 2007 Meeting. Asilomar, CA. April, 2007.
199. *Celebrating Scholars and Scholarships*, Boule Scholarship Dinner Lecture. Denver, CO. May, 2007.
200. *University and Entrepreneurship*, Bard Center for Entrepreneurship awards program. Denver, CO. June, 2007.
201. *Design, Conduct and Interpretation of Clinical Trials: Pearls and Pitfalls*, World Glaucoma Congress. The Association of International Glaucoma Societies. Singapore. July, 2007.
202. *Closing the Achievement Gap: Educating for Success in a Competitive Marketplace*, African American Leadership Summit. Washington, DC. July, 2007.
203. *Reactions and Comment: The Nation’s Health Workforce*, Association of Academic Health Centers 2007 Annual Meeting, Philadelphia, PA. October 2007.
204. *How Common is Progression?*, American Academy of Ophthalmology/Prevent Blindness American Glaucoma Symposium. New Orleans, LA. November 2007.
205. *Reflections on Glaucoma: 1986-2006*, Philippine Glaucoma Congress. The Philippine Glaucoma Society 10<sup>th</sup> Anniversary. Manila, Philippines. February 2008.
206. *Risk Factor: The Birth, The Evolution and The Practice*, Philippine Glaucoma Congress. The Philippine Glaucoma Society 10<sup>th</sup> Anniversary. Manila, Philippines. February 2008.
207. *Current Approach to the Medical Treatment of Glaucoma*, Philippine Glaucoma Congress. The Philippine Glaucoma Society 10<sup>th</sup> Anniversary. Manila, Philippines. February 2008.

208. *Glaucoma Drainage Devices*, Philippine Glaucoma Congress. The Philippine Glaucoma Society 10<sup>th</sup> Anniversary. Manila, Philippines. February 2008.

Named or Honorary Lectures

1. *Epidemiology of Eye Disorders Worldwide: Strategies for Prevention and Control*. Invited University Lecture, University of Colombo, Colombo, Sri Lanka. August 1995.
2. *Clinical Trials and Observational Studies: What Have We Learned?* Third Annual Roger P. Mason Memorial Lecture. Howard University, Washington DC. September 1996.
3. Keynote Address: *Assessing the Optic Nerve with Confocal Laser Imaging Systems*. All India Ophthalmology Society Conference, New Delhi, India. February 1997.
4. *Glaucoma Clinical Trials*. Roger P. Mason Memorial Lecture, National Medical Association, Honolulu, Hawaii. July 1997.
5. *How Glaucoma Affects the Quality of Life*. 18<sup>th</sup> Annual Janice Krushner Memorial Lecture, International Glaucoma Association, London, England. November 1999.
6. *Glaucoma: What's Race Got to Do with It?* Irving Leopold Lecture, 5<sup>th</sup> Annual Ocular Drug and Surgical Therapy Update, Dana Point, California. February 2002.
7. *What is Race and is it Relevant in Clinical Research*. Irving Leopold Honoree, Allergan Pharmaceuticals, Irvine, California. September 2003.
8. *Roles and Responsibilities of Academic Health Sciences Center*. John Aure Buesseler Distinguished Lectureship, Texas Tech University Rawls College of Business, Lubbock, Texas. November 2003.
9. *A Perspective on Race and Glaucoma*. H. Saul Sugar Lectureship in Glaucoma, Henry Ford Hospital & Medical Centers 27<sup>th</sup> Annual Alumni Meeting, Dearborn, Michigan. June 2004.
10. *The Risk Factor and Glaucoma*. Claude Cowan Sr. Memorial Lecture, National Medical Association, New York, New York. July 2005.
11. *The Risk Factor: Past, Present, Future*. Keynote Lecture, Duke University Fall Glaucoma Symposium, Durham, North Carolina. September 2005.
12. *The Risk Factor and Glaucoma*. Konstantin Konstas Memorial Lecture, 39<sup>th</sup> Panhellenic Ophthalmological Congress, Thessaloniki, Greece. June 2006.
13. *1986-2006: Reflections on Glaucoma*. Keynote Lecture. 6<sup>th</sup> International Glaucoma Symposium of the International Glaucoma Society, Athens, Greece. March 2007
14. *1986 – 2006: Reflections on Glaucoma*, Philip Ellis Keynote Lecture. 11<sup>th</sup> Annual Ophthalmology Symposium, University of Colorado Denver School of Medicine, Denver, CO. October, 2007.
15. *Risk Factor: The Concept, the Evolution, and the Practice*. American Glaucoma Society Keynote Lecture. Glaucoma 2007 Subspecialty Day, American Academy of Ophthalmology Annual Meeting, New Orleans, LA. November 2007.

### Bibliography

#### Publications:

1. Wilson MR, Walker AM, Dueker DK, and Crick RP: Risk Factors for Rate of Progression of Glaucomatous Visual Field Loss: A Computer-Based Analysis. *Arch Ophthalmol.* 100: 737-747, 1982.
2. Wilson MR, Richardson TM, Hertzmark E, and Grant WM: Race as a Risk Factor for Progressive Glaucomatous Damage. *Arch Ophthalmol.* 17: 653-659, 1985.
3. Wilson MR, Hertzmark E, Walker AM, Childs K, Epstein DL: A Case-Control Study of Risk Factors in Open-Angle Glaucoma. *Arch Ophthalmol.* 105: 1066-1071, 1987.
4. Singh G, Wilson MR, and Foster CS: Mitomycin Eye Drops as Treatment for Pterygium. *Ophthalmol.* 95: 813-826, 1988.
5. Wilson MR, Lee DA, Yoshizumi MO, Martin W, Higginbotham EJ: Use of Intraocular Gas in Post-Filtration Surgery Flat Anterior Chamber. *Arch Ophthalmol.* 106: 1345,1988.
6. Wilson MR: Glaucoma in Blacks: Where Do We Go From Here? *JAMA.* 261: 281, 1989.
7. Mason RP, Kosoko O, Wilson MR, et al: National Survey of the Prevalence and Risk Factors of Glaucoma in St. Lucia, West Indies. Part I: Prevalence Findings. *Ophthalmol.* 96: 1363-1368, 1989.
8. Wilson MR: Posterior Lip Sclerectomy vs. Trabeculectomy in West Indian Blacks. *Arch Ophthalmol.* 107: 1604-1608, 1989.
9. Singh G, Wilson MR, Foster CS: Long-term Follow-up Study of Mitomycin Eye Drops as Adjunctive Treatment for Pterygia and its Comparison with Conjunctival Autograft Transplantation. *Cornea.* 9(4): 331-334, 1990.
10. Lee DA, Wilson MR, Yoshizumi MO, Hall M: The Ocular Toxicity of Gases When Injected into the Anterior Chamber of Rabbit Eyes. *Arch Ophthalmol.* 109: 571-575, 1991.
11. Wilson MR, Lee DA, Baker RS, et al: The Effects of Topical Mitomycin on Glaucoma Filtering Surgery in Rabbits. *Journal of Ocular Pharmacology.* 7: 1-8, 1991.
12. Charles JB, Ganthier R, Wilson MR, et al: The Use of Biodegradable Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery. *Ophthalmol.* 98: 503-508, 1991.
13. Wilson MR, Wooten F, and Williams J: Frequency and Characteristics of Ocular Trauma in an Urban Population. *Journal of the National Medical Association.* 83: 97-701, 1991.
14. Wilson MR: Primary Open-Angle Glaucoma: Magnitude of the Problem in the United States. *Journal of Glaucoma.* 1: 64-68, 1992.
15. Wilson MR: Ofloxacin Study Group: Ofloxacin vs. Tobramycin for the Treatment of External Ocular Infection. *Arch Ophthalmol.* 110: 1234-1237, 1992.

16. Sanders R and Wilson MR: Diabetes Related Eye Disorders. *Journal of National Medical Association.* 85: 104-108, 1993.
17. Drake M, Wilson MR, Harris D., Goodwin T: Levobunolol Compared to Dipivefrin in African American Patients With Open-Angle Glaucoma. *Journal of Ocular Pharmacology.* 9: 91-95, 1993.
18. Wilson MR and Baker RS: Prognostic Factors for Glaucoma Filtration Surgery. *Journal of Glaucoma.* 2: 223-226, 1993.
19. Sarraf D, Eezzuduemhoi D, Cheng Q, Wilson MR, Lee DA: Aqueous and Vitreous Concentration of Mitomycin-C by Topical Administration After Glaucoma Filtration Surgery. *Ophthalmology.* 100: 1574-1579, 1993.
20. Wilson MR, Baker RS, Lee D, et al: Reproducibility of Postural Changes in Intraocular Pressure with the Tonopen and Pulsair Tonometers. *Am J Ophthalmol.* 116: 479-483, 1993.
21. Wilson MR, Neumann R: Free Conjunctival Patch for Repair of Persistent Late Bleb Leak. *Am J Ophthalmol.* 117: 569-574, 1994.
22. Wilson MR, Khanna S: The Value of Different Screening Techniques in Glaucoma. *Current Opinion in Ophthalmology.* 5(11): 69-75, 1994.
23. Wilson MR (ed): Glaucoma: The Common Pathway to Blindness. Proceedings of the 1993 AAO/NSPB Glaucoma Symposium. *Journal of Glaucoma.* 3: 165-183, 1994.
24. Wilson MR, Lee DA, Bourque L: Does the Public Understand the Differences Between Ophthalmologists and Optometrists? *Ophthalmic Epidemiology.* 1: 121-129, 1994.
25. Coleman A, Hill D, Wilson MR, et al: Clinical Experience with the Ahmed Glaucoma Valve Implant. *Am J Ophthalmol.* 120: 23-31, 1995.
26. Sponsel WE, Ritch R, Stamper R, Higginbotham E, Anderson DR, Wilson MR, Zimmerman T, for the Prevent Blindness America Glaucoma Advisory Committee: Prevent Blindness America Visual Field Screening Study. *Am J Ophthalmol.* 120: 699-708, 1995.
27. Sponsel WE, Ritch R, Stamper R, Higginbotham EJ, Anderson DR, Wilson MR, Zimmerman TJ: Prevent Blindness America Visual Field Screening Study. *Am J Ophthalmol.* 121: 590-591, 1996.
28. Wilson MR, Mohamed M, Atud A, et al: A Population-Based Study of Xerophthalmia in the Extreme North Province of Cameroon, West Africa. *Arch Ophthalmol.* 114: 464-468, 1996.
29. Wilson MR, Mohamed M, Ross-Degnan D, et al: Prevalences and Causes of Low Vision and Blindness in the Extreme North Province of Cameroon, West Africa. *Ophthalmic Epidemiology.* 3: 22-33, 1996.
30. Wilson MR, Gaasterland D: Translating Research into Practice: Controlled Clinical Trials and Their Influence on Glaucoma Management. *Journal of Glaucoma.* 5: 139-146, 1996.
31. Baker RS, Wilson MR, Flowers CW, et al: A Population-Based Study of Severe Work-Related Ocular Injuries: Part 1. Age, Sex, Race Distributions. *Am J Ophthalmol.* 122: 213-219, 1996.

32. Coleman AL, Smyth RJ, Wilson MR, Tam M: Initial Clinical Experience with the Ahmed Glaucoma Valve Implant in Pediatric Patients. *Arch Ophthalmol.* 115: 186-193, 1997.
33. Coleman AL, Mondino BJ, Wilson MR: Clinical Experience with the Ahmed Glaucoma Valve Implant in Eyes with Prior or Concurrent Penetrating Keratoplasties. *Am J Ophthalmol.* 123: 54-61, 1997.
34. Gutierrez PR, Wilson MR, Johnson C, et al: The Influence of Glaucomatous Visual Field Loss on Health-Related Quality of Life. *Arch Ophthalmol.* 115: 777-784, 1997.
35. Wilson MR: The "Myth of 21". *Journal of Glaucoma.* 6: 75-77, 1997.
36. Baker RS, Watkins NL, Wilson MR, et al: Demographic and Clinical Characteristics of Patients with Diabetes Presenting to an Urban Hospital Ophthalmology Clinic. *Ophthalmol: Vol 123, No. 8:1373-1379, 1998.*
37. Lee BL, Gutierrez P, Gordon M, Wilson MR, Cioffi GA, Ritch R, Sherwood M, Mangione C: The Glaucoma Symptom Scale (GSS): A Brief Index of Glaucoma-Specific Symptoms. *Arch Ophthalmol.* 116: 861-866, 1998.
38. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Winters J, Lai A: Functional Status and Well-Being in Patients with Glaucoma as Measured by the Medical Outcomes Study Short Form-36 Questionnaire. *Ophthalmol.* 105: 2112-2116, 1998.
39. Baker RS, Wilson MR, Flowers CW, et al: A Population-Based Study of Severe Work-Related Ocular Injuries: Part II. Diagnoses, Causes, Resource Utilization, and Outcomes. *Ophthalmic Epidemiology.* 6: 159-169, 1999.
40. Hamush NG, Coleman AL, Wilson MR: Ahmed Glaucoma Valve Implant for Management of Glaucoma in Sturge – Weber Syndrome. *Am J Ophthalmol.* 128: 758-760, 1999.
41. Topouzis F, Coleman AL, Choplin N, Bethlem MM, Hill R, Yu F, Panek WC, Wilson MR: Follow-up of the Original Cohort with the Ahmed Glaucoma Valve Implant. *Am J Ophthalmol.* 128: 198-204, 1999.
42. Bartlett JD, Olivier M, Richardson T, Whitaker R Jr, Pensyl D, Wilson MR: Central Nervous System and Plasma Lipid Profiles Associated with Carteolol and Timolol in Postmenopausal Black Women. *Journal of Glaucoma.* 8(6) 388-395, 1999
43. Lee BL, Wilson, MR(ed): Health Related Quality of Life in Cataract and Glaucoma. *Journal of Glaucoma.* 9: 87-94, 2000.
44. Wilson MR, Mendis U, Smith SD, Paliwal A: Ahmed Glaucoma Valve Implant vs Trabeculectomy in the Surgical Treatment of Glaucoma. A Randomized Clinical Trial. *Am J Ophthalmol.* 130: 267-273, 2000.
45. Wilson MR, Coleman AL, Yu F, Sasaki IF, Bing EG, Kim MH: Depression in Patients with Glaucoma as Measured by Self Report Surveys. *Ophthalmol.* 109;1018-1022, 2002.

46. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA: The Ocular Hypertension Treatment Study: Baseline Factors that Predict the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol.* 120: 714-720, 2002.
47. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol.* 120: 701-713, 2002.
48. Wilson, MR: Progression of Visual Field Loss in Untreated Glaucoma Patients and Suspects in St. Lucia, West Indies. *Trans Am Ophthalmol Soc.* Vol 100: 365-410, 2002.
49. Wilson MR, Kosoko S, Cowan C, et al.: Progression of Visual Fields in Untreated Glaucoma and Glaucoma Suspects in St. Lucia West Indies. *Am J. Ophthalmol.* 134:399-405, 2002.
50. Wilson MR: Normal Tension Glaucoma. *Acta Ophthalmologica Scandinavica.* Vol 80: 9-11, 2002.
51. Wilson MR, Mendis U, Paliwal A, Haynatzka V: Long-term Follow-up of Primary Glaucoma Surgery With Ahmed Glaucoma Valve Implant Versus Trabeculectomy. *Am J Ophthalmol.* Vol 136: 464-470, 2003.
52. Racette L, Wilson MR, Zangwill LM, Weinreb RN, Sample PA: Primary Open-Angle Glaucoma in Blacks: A Review. *Surv Ophthalmol.* Vol 48: 295-313, 2003.
53. Wilson MR, Drake M, Brandt J. Management of Ocular Hypertension. *Journal of Glaucoma.* Vol 13: 81-83, 2004.
54. Gong G, Kosoko S, Haynatzki GR, Wilson MR. Genetic Dissection of Myocilin Glaucoma. *Human Molecular Genetics.* Vol 13: 91-102, 2004.
55. Topouzis F, Coleman AL, Yu F, Mavroudis L, Anastasopoulos E, Koskosas A, Pappas Th, Dimitrakos S, Wilson MR. Sensitivity and Specificity of the 76-Suprathreshold Visual Field Test to Detect Eyes with Visual Field Defect by Humphrey Threshold Testing in a Population-based Setting: The Thessaloniki Eye Study. *Am J Ophthalmol.* Vol 137: 420-425, 2004.
56. Varma R, Ying-Lai M, Francis BA, Nguyen B, Deneen J, Wilson MR, Azen SP and the LALES Group. Prevalence of Open-Angle Glaucoma and Ocular Hypertension in Latinos: The Los Angeles Latino Eye Study. *Ophthalmol.* 111: 1439-1448, 2004.
57. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An Evidence-based Assessment of Risk Factors for the Progression of Ocular Hypertension and Glaucoma. *Am J Ophthalmol.* 138: S19-S31, 2004.
58. Weinreb RN, Friedman DS, Fechtner RD, Cioffi GA, Coleman AL, Girkin CA, Liebmann JM, Singh K, Wilson MR, Kannel WB. Risk Assessment in the Management of Patients with Ocular Hypertension. *Am J Ophthalmol.* 138: 458-467, 2004.

59. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA and the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals. *Arch Ophthalmol.* 122(6): 813-820, 2004.
60. Jonescu-Cuypers C, Harris A, Wilson MR, Kagemann L, Mavroudis L, Topouzis F, Coleman A. Reproducibility of the Heidelberg Retinal Flowmeter in Determining Low Perfusion Areas in Peripapillary Retina. *B J Ophthalmol.* 88: 1266-1269, 2004.
61. Topouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E, Dimitrakos S, Wilson MR. Risk of Sudden Visual Loss Following Filtration Surgery in End-Stage Glaucoma. *Am J Ophthalmol.* 140 (4): 661-666, 2005.
62. Racette L, Boden C, Kleinhandler SL, Girkin CA, Liebmann JM, Zangwill LM, Medeiros F, Bowd C, Weinreb RN, Wilson MR, Sample PA. Differences in Visual Function and Optic Nerve Structure Between Healthy Eyes of Blacks and Whites. *Arch Ophthalmol.* 123: 1547-1553, 2005.
63. Wilson, MR. Administration and Leadership of the Health Professions Partnership Initiative: A Medical School Administrator's Perspective. *Academic Medicine.* 81 (6): S55-S57, 2006.
64. Gong G, Haynatzki G, Haynatzka V, Howell R, Kosoko-Lasaki S, Fu YX, Yu F, Gallagher JC, Wilson MR. Bone Mineral Density-Affecting Genes in Africans. *J Nat Med Assoc.* 98 (7): 1102-1108, 2006.
65. Naeim A, Keeler EB., Gutierrez PR, Wilson MR, Reuben D, Mangione CM. Is cataract surgery cost-effective among older patients with a low predicted probability for improvement in reported visual functioning? *Medical Care.* 44 (11): 982-989, 2006.
66. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Pappas T, Wilson MR. Association of blood pressure status with optic disc structure in non glaucoma subjects. *Am J Ophthalmol.* 142 (1): 60-67, 2006.
67. Topouzis F, Coleman A, Harris A, Anastasopoulos E, Yu F, Koskosas A, Pappas T, Mavroudis L, Wilson MR. Prevalence of Age-related Macular Degeneration in Greece: The Thessaloniki Eye Study. *Am J Ophthalmol.* 142 (6): 1076-1079, 2006.
68. Kosoko-Lasaki O, Gong G, Haynatzki G, Wilson MR. Race, Ethnicity and Prevalence of Primary Open Angle Glaucoma. *J Nat Med Assoc.* 98 (10): 1626-1629, 2006.
69. Gong G, Kosoko-Lasaki O, Haynatzki G, Lynch HT, Lynch JA, Wilson MR. Inherited, Familial and Sporadic Primary Open-Angle Glaucoma. *J Natl Med Assoc.* 99 (5): 559-563, 2007.
70. Mavroudis L, Harris A, Topouzis F, Wilson MR, Yu F, Anastasopoulos E, Koskosas A, Siesky B, Pappas T, Founti P, Coleman A. Reproducibility of Pixel-by-Pixel Analysis of Heidelberg Retinal Flowmetry Images: the Thessaloniki Eye Study. *Acta Ophthalmol Scand.* 2007.
71. Topouzis F, Wilson MR, Harris A, Anastasopoulos E, Yu F, Mavroudis L, Pappas T, Koskosas A, Coleman A. Prevalence of Open-Angle Glaucoma in Greece: The Thessaloniki Eye Study. *Am J Ophthalmol.* 144 (4):511-519, 2007.

72. Topouzis F, Coleman A, Harris A, Koskosas A, Founti P, Yu F, Anastasopoulos E, Pappas T, Wilson MR. Factors associated with undiagnosed open-angle glaucoma: The Thessaloniki Eye Study. *Am J Ophthalmol.* 145 (2):327-335, 2007.
73. Wilson MR, Lee PP, Weinreb R, Lee BL, Singh K. A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part I: Methodology and Design. *Am J Ophthalmol.* 145(3):570-574, 2008.
74. Singh K, Lee B, Wilson MR. A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part II: Results and Interpretation. *Am J Ophthalmol.* 145(3):575-581, 2008.
75. Wilson MR, Krugman R. The Changing Face of Academic Health Centers: A Path Forward. *Academic Medicine* (in press)

Publications as Part of Ocular Hypertension Treatment Study Group (on Steering/Executive Committee)

76. Gordon MO, Kass MA for the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants. *Arch Ophthalmol.* 117: 573-583, 1999.
77. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 118: 1187-1194, 2000.
78. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: Contralateral Effect of Topical  $\beta$ -Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study. *Am J Ophthalmol.* 130:441-553, 2000.
79. Brandt JD, Beiser JA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group: The Central Corneal Thickness in the Ocular Hypertension Treatment Study. *Ophthalmol.* 108:1779-1788, 2001.
80. Feuer WJ, Parrish RK, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Reproducibility of Cup/Disk Ratio Measurements Over Time at an Optic Disc Reading Center. *Am J Ophthalmol.* 133:19-28, 2002.
81. Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Treatment Study Group: Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study. *Ophthalmol* 109:432-437, 2002.
82. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group: Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 121:643-650, 2003.
83. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group: Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study. *Am J Ophthalmol.* 138:717-722, 2004.

84. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Kirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Racial Differences in Optic Disc Topography: Baseline Results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 122:22-28, 2004.
85. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study design and baseline factors. *Am J Ophthalmol.* 137:219-227, 2004.
86. Coleman A, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group: Baseline Risk Factors for the Development of POAG in the OHTS (Brief Report). *Am J Ophthalmol.* 138: 684-685, 2004.
87. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study Group: Incorporating the Results of the Ocular Hypertension Treatment Study into Clinical Practice (Letter to the editor). *Arch Ophthalmol.* 123:1021-1022, 2005.
88. Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group: Normal Visual Field Test Results Following Glaucomatous Visual Field End Points in the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 123: 1201-1206, 2005.
89. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. Baseline Topographic Optic Disc Measurements are Associated with the Development of Primary Open Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 123:1188-97, 2005.
90. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vanderbroucke R, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Group: Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. *Am J Ophthalmol.* 140:762-64, 2005.
91. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group. Management of Ocular Hypertension: A Cost-effectiveness Approach from the Ocular Hypertension Treatment Study. *Am J Ophthalmol.* 141: 997-1008, 2006.
92. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study Group. Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci.* 47:3896-3903, 2006.
93. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group (OHTS). The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the OHTS. *Ophthalmology.* 113:1603-12, 2006.

94. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA. Topical Ocular Hypotensive Medication and Lens Opacification: Evidence from the Ocular Hypertension Treatment Study. *Am J Ophthalmol.* 142:800-12, 2006.
95. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group. Detection and Prognostic Significance of Optic Disc Hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology.* 113:2137-43, 2006.
96. The Ocular Hypertension Treatment Study Group and European Glaucoma Prevention Study Group. A Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension. *Ophthalmol* 114:10-19, 2007.
97. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study Group. Comparison of Initial Intraocular Pressure Response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in African Americans and Whites in the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 125:454-9, 2007.
98. Keltner JL, Johnson CA, Cello DK, Bandermann S, Fann JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study. *J Glaucoma.* 16:665-9, 2007.
99. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a History of Diabetes Mellitus Protective Against Developing Primary Open-Angle Glaucoma? *Arch Ophthalmol.* 126:280-2, 2008.
100. Parrish R, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells, Vandenbroucke, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group: Test-Retest Reproducibility of Optic Disc Progression (Brief Report). *Am J Ophthalmol.* (In Press)
101. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension Treatment Study Group. Changes in Central Corneal Thickness Over Time: the Ocular Hypertension Treatment Study. *Ophthalmology.* In Press

#### Book Chapters

1. Wilson MR: Epidemiologic Aspects of Glaucoma. *International Ophthalmology Clinics*, Little Brown and Co., Boston, MA. Vol. 30, No. 3:153-160, 1990.
2. Wilson MR: Glaucoma in Blacks. *Mediguide to Special Problems in Ophthalmology.* Dellacorte Publications Inc., New York. Vol 1, Issue 1, 1991
3. Wilson MR and Drake MV: Glaucoma in Blacks: Epidemiology and Management. *Clinical Signs in Ophthalmology.* Mosby-Year Book, Inc., St. Louis, MO. Vol XIII, No. 2, 1992.
4. Wilson MR: Epidemiology of Glaucoma. In Albert DM, Jakobiec FA, eds. *Principles and Practices of Ophthalmology.* W.B. Sanders Co., Philadelphia, PA. Chapter 110: 1275-1284, 1994.
5. Wilson MR: Peripheral Iridectomy and Chamber Deepening. In Albert DM, Jakobiec FA, eds. *Principles and Practices of Ophthalmology.* W.B. Sanders Co., Philadelphia, PA. Chapter 142: 1618-1622, 1994.

6. Wilson MR: Glaucoma. Epidemiology and Risk Factors. In Higginbotham EJ, Lee DA, eds. Management of Difficult Glaucomas: A Clinician's Guide. Blackwell Scientific Publications, Cambridge, Mass. Chapter 1: 3-8, 1994.
7. Wilson MR and Bacharach J: Glaucoma. In Rakel RE, ed. Conn's Current Therapy. W.B. Saunders Co., Philadelphia, PA. Section 13: 915-918, 1994.
8. Wilson MR and Martone J: The Epidemiology of Chronic Open-Angle Glaucoma and Ocular Hypertension. In Ritch R, Shields MB, Krupin T, eds. The Glaucomas. A Multi-Volume Reference. Mosby Year Book, St. Louis. Chapter 35: 753-768, 1996.
9. Wilson MR: The Epidemiology of Glaucoma. In Epstein DA, ed. Chandler and Grant's Glaucoma. Lea and Febiger, London. Part 11: Chapter 72: 641-647, 1996.
10. Wilson MR: Epidemiology of Glaucoma. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology 2nd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 1, Chapter 28: 531-537, 1999.
11. Wilson MR: Incisional Surgical Techniques for Angle Closure Glaucoma. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology, 2nd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 4, Chapter 225: 2954 - 2958, 1999.
12. Coleman A, Wilson MR: Risk Factor Assessment and Glaucoma Screening. Ophthalmology Clinics of North America. W.B. Saunders Co., Philadelphia, PA. Volume 13, Number 3: 349 -360, 2000.
13. Wilson MR: Primary Open-Angle Glaucoma and Risk Factors. In Higginbotham EJ, Lee DA, eds. Clinical Guide to Glaucoma Management. Butterworth-Heinemann, MA. 3-9, 2004.
14. Brandt JD and Wilson MR: What Have We Learned from the Major Glaucoma Clinical Trials? In Kriegelstein GK and Weinreb RN, (series eds.) and Grehn F and Stamper R, (vol. eds.). Essentials in Ophthalmology: Vol. 1. Glaucoma, 1st Edition: 125-137. New York: Springer-Verlag, 2004.
15. Wilson MR: What is Race? International Ophthalmology Clinics, Little Brown and Co., Boston MA. Volume 43:4:1-8., 2003.
16. Wilson MR and Eezzuduemhoi DR: Ophthalmologic Disorders in Minority Populations. Medical Clinics of North America. W.B. Saunders Co, Philadelphia, PA. Volume 89, Issue 4: 795-804, July 2005.
17. Coleman A, Mansberger S, Wilson MR: Epidemiology of Primary Open-Angle Glaucoma. Principles and Practices of Ophthalmology, 3<sup>rd</sup> Edition. W.B. Sanders Co., Philadelphia, PA. Volume 1, Chapter 36:395-402, 2008.
18. Wilson MR, Gallardo M: Laser and Surgery Treatment of Angle-Closure Glaucoma. Principles and Practices of Ophthalmology, 3<sup>rd</sup> Edition. W.B. Sanders Co., Philadelphia, PA. Volume 2, Chapter 219:2811-2820, 2008.

### Books

1. Wilson MR, Martone JF (eds). The Lighthouse Handbook on Vision Impairment and Vision Rehabilitation. Part 1, Visual Disorders: The Medical Perspective. Oxford University Press, New York, New York, 2000.

### Invited Commentaries and Articles:

1. Wilson MR, Reaves H: Additional Comments on the Effect of Triamcinolone Injection. Arch Ophthalmol. 105: 1166, 1987.
2. Wilson MR: Hypotony in "Consultation Section." Journal of Cataract and Refractive Surgery. Vol. 19, No. 6: 810-811, 1993.
3. Wilson MR, Weinreb R: Who Should Be Examined for Glaucoma? Focus on Glaucoma. Vol. 7, No. 2. Spring 1993.
4. Wilson MR: Management of Iridocorneal Syndrome in "Cases in Controversy." Journal of Glaucoma. 3: 154-159, 1994.
5. Wilson MR: How Clinical Trials Could Change Glaucoma Treatment Patterns. Review of Ophthalmology. September, 1997.
6. Wilson MR: Management of Late Bleb Leaks. Journal of Glaucoma. 8: 263-266, 1999.
7. Wilson MR: Epidemiology in Ophthalmology. Editorial. Arch Ophthalmol. 119:1374-1375, 2001.
8. Wilson MR: A New Role for Diode Laser Trans-Scleral Cyclophotocoagulation? Editorial. Arch Ophthalmol. 119: 424-425, 2001.
9. Wilson MR: Racial Disparities in Vision Impairment and Blindness: Causes and Future Research Direction. Editorial. Ophthalmol. 108:1719-1720, 2001.
10. Wilson MR: Screening Paradigms in Glaucoma. Invited Article for 10<sup>th</sup> Anniversary, Journal of Glaucoma. Sup 1, Vol 10: 5: S25-S27, 2001.
11. Wilson MR: A Need for Innovation in Glaucoma Surgery. Editorial. Arch Ophthalmol. 120:633, 2002.
12. Wilson MR. Glaucoma in the Caribbean: Implications for the African American Population. Glaucoma Management News. December 2002.
13. Lee BL and Wilson MR: The Ocular Hypertensive Treatment Study Commentary. Current Opinion in Ophthalmology. 14:74-77, 2003.
14. Lee BL and Wilson MR: Randomized Controlled Trials in Glaucoma. Glaucoma Perspectives in Practice. Issue 51:1-8, 2003
15. Wilson MR and Brandt JD: Update on Glaucoma Clinical Trials. American Academy of Ophthalmology, Focal Points. Vol 21: 9: 1-9, 2003

16. Wilson MR: The Use of "Race" for Classification in Medicine: Is it Valid? Editorial. *Journal of Glaucoma*. 12:293-294, 2003.
17. Wilson MR: NNT. Treatment of Ocular Hypertension and Early Glaucoma: How Much Benefit and is it Worth the Cost? Editorial. *International Glaucoma Review*. Vol 5:1: 10, 2003.
18. Wilson MR: New Evidence, New Treatments: The Impact of NEI Clinical Trials on Glaucoma Management. *Review of Ophthalmology*. November 2003.
19. Wilson MR: Discussion of paper: Racial Differences in Optic Disc Topography: Baseline Results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *International Glaucoma Review*, Volume 6-1, 2004.
20. Wilson, MR. Discussion of paper: Prevalence of Open Angle Glaucoma in Rural South Indian Population. *International Glaucoma Review*, Volume 7-3, 2006.

#### Letters and Comments

1. Wilson MR: Efficacy and Complications of Full-thickness Filters. Letter to the Editor. *Journal of Glaucoma*. 2: 75, 1993.
2. Wilson MR: Laser Treatment May Halt Neovascular Glaucoma Progression. *Ophthalmol Times*. 17(16): 13, 1994 (Passim).
3. Wilson MR: Vision Loss in the Glaucoma Population: Magnitude and Race. *Journal of Glaucoma*. 1: 219, 1992.
4. Wilson MR: Mitomycin Trabeculectomy: Clinical Precautions. *JSEI-UCLA Clinical Update*. 3(1): 2-4, 1994 (Passim).
5. Baker RS, Flowers CW, Casey R, Fong D, and William MR: Efficacy of ofloxacin vs. cefazolin and Tobramycin in the Therapy for Bacterial Keratitis. Letter to the Editor. *Arch Ophthalmol*. 114: 632, 1996.
6. Wilson MR: Glaucoma in Blacks: Unraveling the Web of Physiologic, Genetic, Socioeconomic Factors. *Ocular Surgery News*. Vol. 15: (10) 1997 (Passim).
7. Jack S, Wilson MR: Optic Disc Hemorrhages and Glaucoma. Letter to the Editor. *Ophthalmol*. 104: 566, 1997.
8. Ali B, Wilson MR: Ciliary Body Endophotocoagulation during Pars Plana Vitrectomy in Eyes with Vitreoretinal Disorders and Concomitant Uncontrolled Glaucoma. Letter to the Editor. *Ophthalmol*. 104: 733, 1997.
9. Wilson MR: Medical Ethics Issues Devolve to Individuals. *Opinion-Editorial*. *Omaha World Herald*. December 2, 1999.
10. Wilson MR. Texas Tech University Health Sciences Center's Long-range Goal is to Make Lubbock the 'Healthiest City in Texas'. Editorial. *Lubbock Avalanche Journal*. September 28, 2003.

11. Wilson MR. OAG in the Visual Impairment Project. Letter to the Editor. *Ophthalmol.* 111: 197, 2004.
12. Wilson MR. Make Healthy Choices When It's Time to Slake Your Thirst. Opinion-Editorial. *Lubbock Avalanche Journal.* June 8, 2004.
13. Wilson MR. Health Sciences Center Celebrating 35 years of Service to West Texas. Opinion-Editorial. *Lubbock Avalanche Journal.* November 27, 2004.
14. Wilson MR. Tuition Deregulation Formula Does Not Benefit Tech Health Sciences Center. Opinion-Editorial. *Lubbock Avalanche Journal.* January 8, 2005.
15. Wilson MR. Where Tuition Deregulation Falls Short. Opinion-Editorial. *Odessa American.* January 19, 2005.
16. Wilson MR. A Simple Glaucoma Exam Can Prevent Blindness. Opinion-Editorial. *Southwest Digest.* January 20, 2005.
17. Wilson MR. Does Tuition Deregulation Really Help Medical Schools. Opinion-Editorial. *Amarillo Globe News.* January 23, 2005.
18. Wilson MR. Health Science Centers Need New Revenue to Meet Needs of Texas. Opinion-Editorial. *El Paso Times.* January 23, 2005.
19. Wilson MR. HSC Becoming Recognized Leader in the Health Disparities Research Area. Opinion-Editorial. *Lubbock Avalanche Journal.* February 19, 2005.
20. Wilson MR. Faculty Vital to Tech, Thomason. Opinion-Editorial. *El Paso Times.* February 27, 2005.
21. Wilson MR. Get Mom, Dad Off the Bench. Opinion-Editorial. *Lubbock Avalanche Journal.* March 1, 2005.
22. Wilson MR. Cutting-Edge Research Vital Component to Texas Tech HSC's Research Mission. Opinion-Editorial. *Lubbock Avalanche Journal.* April 2, 2005.
23. Wilson MR. Health Sciences Center Students Represent Best of Tomorrow's Health Care Professionals. Opinion-Editorial. *Lubbock Avalanche Journal.* May 14, 2005.
24. Wilson MR. Scholarships for Disadvantaged Students Bring Diversity to Health Care Profession. Opinion-Editorial. *Lubbock Avalanche Journal.* June 25, 2005.
25. Wilson MR. Building a Better HSC. Opinion-Editorial. *Lubbock Avalanche Journal.* September 17, 2005.
26. Wilson MR. TTU Health Science's Center's Mission Key to Fulfilling the Institution's Vision. Opinion-Editorial. *Lubbock Avalanche Journal.* October 29, 2005.
27. Wilson MR. TTUHSC's Efforts to Increase Diversity Will Result in Better Health Care for All. Opinion-Editorial. *Lubbock Avalanche Journal.* December 10, 2005.

28. Wilson MR. Funding for Area Health Education Centers Vital to Future of West Texans' Health Care. Opinion-Editorial. Lubbock Avalanche Journal. January 21, 2006.
29. Wilson MR. TTUHSC Continues to Make Inroads in Addressing Work Force Shortages. Opinion-Editorial. Lubbock Avalanche Journal. March 4, 2006.
30. Wilson MR. Glaucoma Can Steal Eyesight Before Diagnosis. Health Column. Lubbock Avalanche Journal. March 9, 2006.
31. Racette L, Boden C, Kleinhandler S, Girkin C, Liebmann J, Zangwill L, Medeiros F, Bowd C, Weinreb R, Wilson M, Sample P. Optic Nerve Structure in Healthy Eyes: Author Reply. Arch Ophthalmol. (In Press)
32. Wilson MR. Regional Research Initiative Established at Texas Tech HSC for Study of Cancer. Lubbock Avalanche Journal. April 15, 2006.
33. Wilson MR. TTU Health Sciences Center Grads Embark on Life of Service to Others. Lubbock Avalanche Journal. May 27, 2006.
34. Wilson MR. Health Campus in Agony – CU Underfunded by any Reckoning. Opinion – Editorial. The Denver Post. November 19, 2006.

Book Reviews:

1. Wilson MR: Glaucoma, edited by James McAllister and Richard P. Wilson. Arch Ophthalmol. 108: 183-84, 1990.
2. Wilson MR: Breaking the Color Line in Medicine: African Americans in Ophthalmology, edited by Lenworth Johnson and OC. Bobby Daniels. Arch Ophthalmol. 121: 586, 2003.

Thesis and Monographs:

1. Wilson MR: Eye Care Survey in Los Angeles County. Thesis for Master of Science in Epidemiology. UCLA, 1990.
2. Wilson MR: Low Vision and Vitamin A Deficiency in the Extreme North Province of Cameroon. Monograph Prepared for Nutrition Service, Cameroon Ministry of Health and the Vitamin A Field Support Project, International Science and Technology Institute, August, 1993
3. Wilson, MR: St. Lucia Follow-up Study: Progression of Visual Field in Untreated Glaucoma and Glaucoma Suspects. Thesis for Trans. Am. Ophthalmol. Soc. Vol. 100, 2002.

Reports and Monographs (as part of writing committee)

1. AAO Basic and Clinical Science Course, Section 15: Glaucoma, 1999-2000 and 2000-2001.
2. Visual Impairments: Determining Eligibility for Social Security Benefits. National Research Council. Editors Peter Lennie and Susan B. VanHemel. National Academy Press 2002.

3. Academic Health Centers: Leading Change in the 21<sup>st</sup> Century. Institute of Medicine. National Academy Press 2003.
4. Screening for Open-Angle Glaucoma: Where Are We Now and Where To From Here? Report from the Global AIGS Committee on Screening for Open Angle Glaucoma. International Glaucoma Review, Volume 7-3, 2006.
5. Code Red: The Critical Condition of Health in Texas. Report from the Task Force on Access to Health Care in Texas. April, 2006.

Videos and CD ROMS:

1. Berlin RS, Cantor LB, Hodapp EA, Lee DA, Wilson MR. Glaucoma Basic and Clinical Science Course: What you need to know. National Audio Video, 1995; v 125-44 (October 30): A,B.
2. Fechtner R, Parrish R, Budenz D, Heuer D, Higginbotham E, Wilson MR. The Ocular Hypertension Treatment Study: Translating Evidence into Practice. Sept. 2002.
3. Glaucoma and You. Video prepared by Pfizer, American Academy of Ophthalmology and Institute of Church Administration and Management featuring Willie Mays, Diahann Carroll, and Drs. Eve Higginbotham, Kevin Greenidge, and M. Roy Wilson.

Abstracts:

1. Wilson MR, Hertzmark E, Walker AM, et al: Risk Factors for Primary Open-Angle Glaucoma: A Case-Control Study. Invest Ophthal Vis Sci. 26(Suppl), 1985.
2. Maynard K, Wilson MR, and Richardson TM: The Effect of Colchicine and Cytochalasin B on the Attachment and Spreading of TM Cells In Vitro. Invest Ophthal Vis Sci. 26 (Suppl), 1985.
3. Wooten F, Singh G, Foster CS, and Wilson MR: Role of Endothelium in Non-healing Corneal Ulcers and Recurrent Epithelial Defects. Invest Ophthal Vis Sci. 28(Suppl): 2, 1987.
4. Singh G, Wilson MR, Foster CS: Mitomycin Eye Drops as Treatment for Pterygium. Supplement to Ophthalmology, October 1987.
5. Mason RP, Kosoko O, Martone J, Cowan CL, Gear J, Ross-Degnan D, Wilson MR: National Survey of the Prevalence and Risk Factors of Glaucoma in St. Lucia, West Indies. Supplement to Ophthalmology. October 1987.
6. Wilson MR, Lee DA, Yoshizumi MO, Hall M, Singh G, and Salem F: Ocular Toxicity of Substances Injected into the Anterior Chamber of Rabbit eyes. Invest Ophthal Vis Sci. 29 (Suppl): 18, 1988.
7. Goodwin LT and Wilson MR: Posterior Lip Sclerectomy vs. Trabeculectomy in a Black Population. Invest Ophthal Vis Sci. 29(Suppl): 367, 1988.
8. Mason RP, Kosoko O, Martone J, Cowan CL, Wilson MR, Gear J, Ross-Degnan D: Glaucoma Prevalence Survey in Saint Lucia, West Indies. Invest Ophthal Vis Sci. 29(Suppl): 61, 1988.

9. Singh G, Wilson MR, Foster CS: Mitomycin Eye Drops as Adjunctive Treatment for Pterygia: Long-term Follow-up and Comparison with Conjunctival Autograft Transplantation. Supplement to Ophthalmology, October 1988.
10. Singh G and Wilson MR: Selective Suture Cutting to Control Corneal Astigmatism After Cataract Surgery. CLAO, New Orleans, January 18-22, 1989.
11. Singh G, Wilson MR, Foster CS: Mitomycin Eye Drops: A New Adjunctive Treatment for Pterygium (Poster). CLAO, New Orleans, January, 1989.
12. Ganthier R, Wilson MR, Anders M, Scott TV, Reaves H, and Wooten F: Three-Year Efficacy of Argon Laser Trabeculoplasty in a Black Population. Invest Ophthal Vis Sci. 30(Suppl): 352, 1989.
13. Goodwin T, Wilson MR, Lee DA, Wooten F, Glasgow B: The Effects of Topical Mitomycin C on Filtration Surgery in Rabbits. Invest Ophthal Vis Sci. 30(Suppl): 417, 1989.
14. Singh G, Wilson MR, and Foster CS: Effectivity and Late Complications of Mitomycin in Treatment of Pterygium. Supplement to Ophthalmology. November 1989.
15. Sanford R, Gables C, Stewart R, Laibovitz R, Buka T, Long D, Wilson MR, and Moore V: A Clinical Comparison of the Fluoroquinolone Ofloxacin with Tobramycin and Gentamycin in the Treatment of External Ocular Infection. Supplement to Ophthalmology. November 1989.
16. Wilson MR, Sharma M, and Gueno W: Comparison of Henson Keeler Screening Visual Fields with Humphrey Threshold Visual Fields. Invest Ophthalmol Vis Sci. 31(Suppl): 16, 1990.
17. Wooten F, Wilson MR, and Williams J: Frequency and Characteristics of Ocular Trauma in an Urban Population. Invest Ophthalmol Vis Sci. 31(Suppl): 19, 1990.
18. Ganthier R, Charles JB, Wilson MR, Lee DA, et al: The Use of Biodegradable Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci. 31(Suppl): 2, 1990.
19. O'Neal TD, Wilson MR: Glaucoma Prevalence in a Hispanic Population. Invest Ophthalmol Vis Sci. 31(Suppl): 13, 1990.
20. Martone JF, Sponsel WE, Brady MA, Wilson MR, et al: Visual Field Screening in a West Indian Black Population Using Humphrey 30-2 and Henson CFS 2000 Perimetry. Invest Ophthal Vis Sci. 31(Suppl): 432, 1990.
21. Wilson MR, Baker RS: Epidemiology of Myopia. Fourth International Conference on Myopia. Myopia International Research Foundation, 1990.
22. Wilson MR: Eye Care Survey in Los Angeles County. Journal of the Association for Academic Minority Physicians. Vol I, No. III: 102, 1990.
23. Wilson MR, Lee DA, Bourque L, Ingles S: A Population-Based Survey of the Public's Knowledge of Differences Between Eye Care Providers. Invest Ophthalmol Vis Sci. 32(Suppl): 1154, 1991.
24. Watkins NL, Baker RS, Wilson MR: Demographic and Clinical Characteristics of Diabetic Patients Presenting to an Urban Hospital Ophthalmology Clinic. Invest Ophthalmol Vis Sci. 32(Suppl): 1142, 1991.

25. Baker RS, Wilson MR, Flowers C: Ophthalmic Information in Primary Care (Non-Ophthalmic) Journals. *Invest Ophthalmol Vis Sci.* 32(Suppl): 1155, 1991.
26. Harris DY, Baker RS, Lee DA, Wilson MR: A Population-based Incidence Study of Severe Ocular Trauma. *Invest Ophthalmol Vis Sci.* 32(Suppl): 1122, 1991.
27. Wilson MR, Baker RS, Lee DA, Wheeler N: A Population-based Study of Severe Ocular Trauma from Assaults. *Invest Ophthalmol Vis Sci.* 33(Suppl): 782, 1992.
28. Mohammadi P, Baker RS, Wilson MR: Evaluation of Postural Changes in Intraocular Pressure with the Tonopen and Pulsair Tonometers. *Invest Ophthalmol Vis Sci.* 33 (Suppl): 733, 1992.
29. Flowers CW, Baker RS, Wilson MR: Severe Work-Related Ocular Injuries: A Population-based Study. *Invest Ophthalmol Vis Sci.* 33(Suppl): 781, 1992.
30. Fong I, Baker RS, Wilson MR, Lee DA: Population-based Study of Enucleation, Evisceration and Exenteration. *Invest Ophthalmol Vis Sci.* 33(Suppl): 784, 1992.
31. Baker RS, Casey R, Lee DA, Wilson MR: Epidemiology of Penetrating Keratoplasty. *Invest Ophthalmol Vis Sci.* 33(Suppl): 1211, 1992.
32. Syrquin MG, Baker RS, Wilson MR, Lee DA: A Population-based Epidemiologic Study of Pars Plana Vitrectomy. *Invest Ophthalmol Vis Sci.* 33(Suppl): 1323, 1992.
33. Baker RS, Wilson MR: Severe Ocular Trauma: A Population-based Incidence Study for the State of California. *Second International Symposium on Ocular Trauma.* Geneva, Switzerland, 1992.
34. Wilson MR: Blebs: Prognostic Factors for Survival and Influencing Its Function. *Experimental Eye Research.* Vol 55, Supplement 1: 14, 1992.
35. Wilson MR, Martone J, Mansour M, et al: A Population-based Survey of Low Vision and Blindness in Cameroon, West Africa: Prevalence, Causes, and Risk Factors. *Invest Ophthalmol Vis Sci.* 34(Suppl): 1294, 1993.
36. Baker RS, Wilson MR, Lee DA, et al: The Epidemiology of Endophthalmitis: A Statewide Population-based Survey. *Invest Ophthalmol Vis Sci.* 34(Suppl): 1260, 1993.
37. Eezzuduemhoi RD, Sarraf D, Wilson MR, et al: Aqueous and Vitreous Concentrations of Mitomycin Following Topical Administration. *Invest Ophthalmol Vis Sci.* 34(Suppl): 726, 1993.
38. Dang Y, Baker RS, Wilson MR, et al: Pediatric Ocular Trauma: A Statewide Population-based Survey. *Invest Ophthalmol Vis Sci.* 34(Suppl): 2026, 1993.
39. Casey R, Wilson MR, Mansour M, et al: Nutritional, Biochemical, and Clinical Assessment of Vitamin A Deficiency in Cameroon, West Africa. *Invest Ophthalmol Vis Sci.* 34(Suppl): 2918, 1993.
40. Bacharach J, Lee DA, Coleman A, et al: Non-Contact Transcleral Nd: YAG Laser Cyclophotocoagulation: Midterm Report. *Invest Ophthalmol Vis Sci.* 34(Suppl): 739, 1993.

41. Atina EA, Wilson MR, Vitamin A Field Support Project (VITAL): Prevalence of Xerophthalmia and Risk of Vitamin A Deficiency Among Children in the Extreme North Province of Cameroon. IVACG Conference. Proceedings of the International Vitamin A Consultative Group, 1993.
42. Wilson MR, Khanna S, Baker R: Visual Field Defects in Diabetic Patients With Primary Open-Angle Glaucoma. Invest Ophthalmol Vis Sci. 35(Suppl): 4286, 1994.
43. Khanna S, Baker R, Wilson MR: Pattern of Early Visual Field Loss in Patients with Low Tension Glaucoma. Invest Ophthalmol Vis Sci. 35(Suppl):2708, 1994.
44. Syrquin M, Baker R, Ali B, et al: The Influence of Prenatal Care Upon the Risk of Retinopathy of Prematurity in High Risk Infants. Invest Ophthalmol Vis Sci. 35(Suppl): 1268, 1994.
45. Tam M, Choplin N, Coleman A, et al: Preliminary Results of Glaucoma Valve Implant Clinical Trial. Invest Ophthalmol Vis Sci. 35(Suppl): 3048, 1994.
46. Smyth R, Tam M, Coleman A, et al: Pediatric Glaucoma Valve Implantation. Invest Ophthalmol Vis Sci. 35(Suppl): 777, 1994.
47. Khanna S, Flowers C, Coleman A, Baker RS, Wilson MR: Grading Glaucomatous Field Defects. Observer Variability of the Aulhorn-Kalmayer Classification. Invest Ophthalmol Vis Sci. 36(Suppl): 1584, 1995.
48. March GA, Goldberg RA, Scott CT, Baker RS, Khanna S, Casey R, Wilson MR: Factors Associated with Delayed Discovery of Intraorbital Foreign Bodies. Invest Ophthalmol Vis Sci. 36(Suppl): 2357, 1995.
49. Scott CT, Baker RS, March GA, Dang YP, Wilson MR: Factors Associated with Delayed Presentation in an Urban Pediatric Eye Clinic. Invest Ophthalmol Vis Sci. 36(Suppl): 365,1995.
50. Khanna S, Ali B, Chandramohan S, Brown SP, Coleman A, Baker RS, Wilson MR: Glaucomatous Field Defects. Validity of Subjective Aulhorn-Kalmayer Classification. Invest Ophthalmol Vis Sci, 37 (Suppl): 2315, 1996.
51. Chandramohan S, Khanna S, Ali B, Coleman A, Baker RS, Wilson MR: Comparison of Normative versus Non-normative based Methodology of Visual Field Analysis. Invest Ophthalmol Vis Sci, 37 (Suppl): 2318, 1996.
52. Gutierrez PR, Mangione CM, Wilson MR: Relationship Between Visual Field Loss and Vision-Specific Quality of Life. Invest Ophthalmol Vis Sci. 37(Suppl): 2981, 1996.
53. Baker RS, Flowers C, Casey, R, Fong, D, Wilson MR: Efficacy of Ofloxacin vs. Cefazolin and Tobramycin in the Therapy for Bacterial Keratitis. Arch Ophthalmol. 114: 632, 1996.
54. Gutierrez PR, Mangione CM, Gordon M, Cioffi R, Ritch R, Sherwood M, Wilson MR: The Effect of Glaucoma-Specific Symptoms and Functioning on Vision-Targeted Health-Related Quality of Life. Invest Ophthal Vis Sci. 38 (Suppl): 729, 1997.
55. Lee BI, Mangione CM, Gutierrez M, Gordon M, Cioffi GA, Ritch R, Sherwood M, Wilson MR: Reliability and Validity of a Survey to Assess Glaucoma-Specific Symptoms and Functional Limitations. Invest Ophthal Vis. Sci. 38 (Suppl): 826, 1997.

56. Wilson MR, Winters J, Yu F, Bing EG, Sasaki I: Quality of Life Among Patients with Eye Disease. Invest Ophthal Vis Sci 38 (Suppl): 840, 1997.
57. Bing EG, Winters J, Yu F, Wilson MR, Sasaki I, Coleman AL: Depression in Patients with Eye Disease. Invest Ophthal Vis Sci. 38 (Suppl): 840, 1997
58. Ali B, Flowers C, Sharza S, Wilson MR, Baker RS: Prevalence of Ophthalmology Related Literature in Primary Care. Invest Ophthal Vis Sci. 38 (Suppl): 844, 1997.
59. Topouzis F, Yu F, Coleman AL, Wilson MR: The Risk of Complications After Cyclodestruction Versus Drainage Device Surgery. Invest Ophthal Vis. Sci. 39 (Suppl): 4077, 1998
60. Kosoko OB, Wilson MR, Copeland RA, Cowan CL, Enger C: Glaucoma Survey in St. Lucia, West Indies: Follow-up study. Invest Ophthal Vis Sci. 40 (Suppl): 929,1999.
61. Kosoko OB, Wilson MR, Copeland RA, Cowan CL, Enger C: Glaucoma Survey in St. Lucia, West Indies: International Agency for the Prevention of Blindness: Sixth General Assembly, Beijing, China, 1999
62. Thessaloniki Eye Study: Sita Versus 76 Suprathreshold (76 STHR) Visual Fields as Screening Tests in a Population Based Study. Invest Ophthal Vis Sci. 41 (Suppl): 1549, 2000.
63. Coleman AL, Topouzis F, Yu F, Mavroudis L, Tsina E, Tzetzis D, Stango NT, Wilson MR: The Reliability of 76 Suprathreshold (76-ST) Visual Fields As Screening Tests in a Population-Based Study. European Glaucoma Society Millennium Meeting, London, England, 2000.
64. Wilson MR, Coleman AL, Sasaki IF, Yu F, Ellingsen KL: Depression In Glaucoma Patients. European Glaucoma Society Millennium Meeting, London, England, 2000.
65. Mavroudis L, Harris A, Topouzis F, Kagemann L, Yu F, Lallou N, Stangos NT, Wilson MR: Reproducibility Of the Heidelberg Retinal Flowmeter in Determining Low Perfusion Areas in Peripapillary Retina. Invest Ophthalmol Vis Sci. 42 (Suppl):1143, 2001.
66. Anastasopoulos E, Topouzis F, Yu F, Jonescu-Cuypers C, Harris A, Mavroudis L, Kagemann L, Wilson MR, Stangos N, Coleman A: Normative Topographic Optic Disk Parameters as Measured with the Heidelberg Retina Tomograph (HRT) in Eyes of a Population-Based Sample of Non-Glaucomatous Elderly People. Invest Ophthalmol Vis Sci. (Suppl): 266, 2002.
67. Racette L, Boden C, Girkin C, Liebmann J, Zangwill I, Bowd Cm, Weinreb R, Wilson MR, Sample P: Visual Function and Optic Nerve Structure in African Americans with Healthy Eyes. Invest Ophthalmol Vis Sci. (Suppl): 2125, 2002.
68. Mavroudis L, Harris A., Coleman A, Topouzis F, Yu F, Kagemann L, Anastasopoulos E, Koskosas A, Stangos N, Wilson MR: Distribution of Areas of Low Flow in the Retinal Peripapillary Blood Flow of Elderly Population. Invest Ophthalmol Vis Sci. (Suppl): 2619, 2002.
69. Mavroudis L, Harris A, Wilson MR, Topouzis F, Yu F, Kagemann L, Anastasopoulos E, Koskosas A, Pappas F, Coleman A: Aging Increases Areas of Low Capillary Blood Flow in the Peripapillary Retinal Circulation of Normal Individuals. Invest Ophthalmol Vis Sci. (Suppl): 359, 2003.

70. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is there a penalty for delayed treatment in ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS). Presented at ARVO, May 4-9, 2003.
71. Varma R, Francis B, Nguyen B, Wilson MR, Lai M, Azen S, LALES Group: Prevalence of Open-Angle Glaucoma and Ocular Hypertension in Latinos. *Invest Ophthalmol Vis Sci. (Suppl):* 3173, 2003.
72. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Koskosas A, Wilson MR: Systemic Factors Affecting Optic Disc Topographic Heidelberg Retina Tomograph Parameters in the General Population. *Invest Ophthalmol Vis Sci. (Suppl.):* 3381, 2003.
73. Gong G, Kosoko-Lasaki O, Haynatzki GR, Wilson MR. The Overall Frequency of Myocilin Mutations Is Higher in the African American General Population. . *Invest Ophthalmol Vis Sci. (Suppl.):* 2723, 2004.
74. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Pappas T, Wilson MR: Comparison of the Optic Disc Topographic Heidelberg Retina Tomograph (HRT) Parameters Between Subjects with Normal Blood Pressure (BP) and Subjects with Systemic Hypertension. . *Invest Ophthalmol Vis Sci. (Suppl.):* 3352, 2004.
75. Pena FY, Lai MY, Francis, BA, Nguyen BB, Deneen J, Wilson MR, Azen SP, Varma R. Clinical Characteristics of Latinos with Open-Angle Glaucoma and Ocular Hypertension. . *Invest Ophthalmol Vis Sci. (Suppl.):* 4486, 2004.
76. Gong G, Kosoko-Lasaki O, Haynatzki G, Lynch JF, Lynch HT, Wilson MR. Familial Aggregation in Genetic Studies of Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci. (Suppl.):* 3809, 2005.
77. Anastasopoulos E, Topouzis F, Wilson M, Harris A, Yu F, Kosokas A, Pappas T, Mavroudis L, Karkamani G, Coleman A. Prevalence of Late Age-Related Maculopathy (AMD) in Greece: Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci. (Suppl.):* 2210, 2006.
78. Topouzis F, Coleman A, Harris A, Anastasopoulos E, Yu F, Kosokas A, Pappas T, Wilson M. Prevalence of Undiagnosed Primary Open Angle Glaucoma and Pseudoexfoliative Glaucoma in Greece: Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci. (Suppl.):* 3423, 2006.
79. Racette L, Boden C, Kleinhandler SL, Girkin CA, Liebmann JM, Zangwill LM, Medeiros FA, Bowd C, Weinreb RN, Wilson MR, et al. Differences in Visual Function and Optic Nerve Structure Between Healthy Eyes in Blacks and Whites. *International Glaucoma Review, Volume 7-3, 2006.*
80. Topouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E, Dimitrakos S, Wilson MR. Risk of Sudden Visual Loss Following Filtration Surgery in End-Stage Glaucoma. *International Glaucoma Review, Volume 7-3, 2006.*
81. Anastasopoulos E, Topouzis F, Harris A, Wilson MR, Yu F, Koskosas A, Pappas T, Founti P, Coleman AL. Comparison of characteristics of pseudoexfoliative vs non-pseudoexfoliative subjects in a population-based study. Evidence from the Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci. (Suppl.):* 1563, 2007.

82. Topouzis F, Wilson MR, Harris A, Anastasopoulos E, Yu F, Pappas T, Koskosas A, Founti P, Coleman AL. Prevalence of primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEXG) by IOP level in a population-based study. Evidence from the Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci. (Suppl.):* 4344, 2007.
83. Topouzis, F, Coleman AL, Harris A, Yu F, Anastasopoulos E, Pappas T, Koskosas A, Founti P, Wilson MR. Management Patterns of Glaucoma Treatment in the Thessaloniki Eye Study (TES). *Invest Ophthalmol Vis Sci. (Suppl.):* 3604, 2008.
84. Coleman, AL, Wilson MR, Harris A, Anastasopoulos E, Yu F, Koskosas A, Pappas T, Founti P, Topouzis F. Risk Factors for Open-Angle Glaucoma in the Thessaloniki Eye Study (TES). *Invest Ophthalmol Vis Sci. (Suppl.):* 5450, 2008.

Published Abstracts as Part of Ocular Hypertension Treatment Study Group (on Steering/Executive Committee)

85. Wong KF, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automated Forms Processing: Trials, Tribulations and Triumphs. *Controlled Clinical Trials* 15:3S, p. 76S, 1994.
86. Gordon MO, Li Z, Schechtman KB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Minimizing Variability and Regression to the Mean in IOP Measurements. *Invest Ophthalmol Vis. Sci* 36:4, S81, 1995.
87. Wong KF, Gordon MO, Achtenberg JF, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic Document Archival for a Data Coordinating Center. *Controlled Clinical Trials* 16:3S, p. 38S, 1995.
88. Gordon MO, Schechtman KB, Li Z, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: A Protocol to Minimize Bias and Regression to the Mean in Measurement of Intraocular Pressure. *Controlled Clinical Trials* 16:3S, p. 98S, 1995.
89. Gordon MO, Johnson CA, Spurr JO, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Pluses and Minuses of Relaxing Fixation Loss Criterion. *Invest Ophthalmol Vis. Sci* 37:3, S507, 1996.
90. Wong K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: An inexpensive electronic system for handling adverse event reports. *Controlled Clin Trial* 17:2S, 1996.
91. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automatic forms processing with Windows 95: Hyperbole? *Controlled Clin Trial* 17:2S, 1996.
92. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic systems for handling adverse event reports. *Controlled Clin Trial* 18(3S):145S, 1997.
93. Bennett GR, Cioffi GA, Dorr D, Gordon MO, Beck A, Fechtner R, Kass M, and the Ocular Hypertension Treatment Study (OHTS) Group: Racial differences in response to glaucoma medications in ocular hypertensive patients. *Invest Ophthalmol Vis. Sci* 38(3):S278, 1997.

94. Gross R, Piltz J, Shin DH, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Contralateral effect of topical beta-blockers on intraocular pressure in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis. Sci 38(4):S1056, 1997.
95. Dorr D, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH® Software. Proceedings of the twenty-third Annual SAS Users Group International Conference: 856-859, 1998.
96. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 39(4):S493, 1998.
97. Gordon MO, Kass MA, Heuer D, Higginbotham E, Parrish R and the Ocular Hypertension Treatment Study (OHTS) Group: Baseline demographics and clinical characteristics of patients enrolled in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 39(4):S878, 1998.
98. Morris PA, Wilder AK, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Site visit strategies to increase collaboration of the clinic, resource centers and coordinating center. Controlled Clin Trials 19(3S):51S, 1998.
99. Dorr DA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: A simple graphical method for displaying multiple dimensions by group over time: and example using the SF-36. Controlled Clin Trials 19(3S):72S, 1998.
100. Fischbach E, Achtenberg J, Clark K, Tourville D, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: (Under) Estimating paper storage requirements for a multicenter clinical trial. Controlled Clin Trials 19(3S):84S, 1998.
101. Bednarski M, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) and the Collaborative Longitudinal Evaluation of Keratoconus Study (CLEK) Groups: A quick and dirty method for delivering SAS® reports via the world wide web. MWSUG Conference Proceedings, 405-410, 1998.
102. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group: Delivering coordinating center reports to clinics via the world wide web. Controlled Clin Trials 20(2S):60S, 1999.
103. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group: Delivering coordinating center reports to clinics via the world wide web. Controlled Clin Trials 20(2S):60S, 1999.
104. Morris PA, Wilder AK, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Accessing SAS reports by the central coordinators via the world wide web. Controlled Clin Trials 20(2S):68S, 1999.
105. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Reproducibility of reading of optic disc cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 40(4):S283, 1999.

106. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Classification of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 40(4):S69, 1999.
107. Keltner JL, Johnson CA, Cello KE, Quigg JM, Kass MA, Gordon MO and the OHTS group. Severity of the types of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 41(4):S84, 2000.
108. Long E, Dunn D, Gordon M, Ocular Hypertension Treatment Study (OHTS) Group. A publications and presentation policy for a multicenter clinical trial. Control Clin Trials: 21(2S): 77S, 2000.
109. Randant D, Long E, Gordon M, the Ocular Hypertension Treatment Study (OHTS) Group. Handling forms in a multicenter clinical trial. Control Clin Trials 21(2S): 100S, 2000.
110. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA, Ocular Hypertension Study Group. Visual field technician performance in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 42(4): S152, 2001.
111. Brandt JD, Beiser J, Kass MA, Gordon MO, for the OHTS Study Group. The relationship of corneal thickness and IOP response to topical  $\beta$ -blocker in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 42(4): S421.
112. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS ) Group. Improving timeliness of annual IRB approvals. Control Clin Trials 22(2S): 79S, 2001.
113. Bednarski MA, Beiser JA, Gordon MA, Morris PA, Wilder AK, and the Ocular Hypertension Study (OHTS) Group. Providing performance reports to clinics via the world wide web. Control Clin Trials 22(2S): 80S, 2001.
114. Morris PA, Wilder AK, Bednarski M, Gordon MO, and the Ocular Hypertension Treatment Study Group. Omnibus clinic tracking report. Control Clin Trials 22(2S):83S, 2001.
115. Bednarski MA, Clark KA, Hornbeck EM, Gordon MO. Dynamic data retrieval using SAS/IntrNet. SAS Users Group International, paper 197, April 14-17, 2002.
116. Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Study Group. Viewing case report forms on the web without scanning data. Control Clin Trials 23(2S):40S, 2002.
117. Achtenberg JF, Hornbeck EM, Gordon MO, and the Ocular Hypertension Treatment Study Group. Enhanced documentation of case report forms. Control Clin Trials 24(3S):180S, 2003.
118. Bednarski MA, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study Group. Tracking and reporting multi-stage processes in a clinical trial. Control Clin Trials 24(S): 187S, 2003.
119. Kymes SM, Gordon MO, and the Ocular Hypertension Treatment Study Group. Economic evaluation in randomized clinical trials - a promise half met? Control Clin Trials 24(3S): 187S, 2003.
120. Morris PA, Wilder AK, Gordon MO, and the Ocular Hypertension Treatment Study Group. Encouraging participation after protocol change. Control Clin Trials 24(S)214S, 2003.

121. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS). Types of visual field abnormalities that subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 45:E-Abstract 2134.
122. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment Study. A predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). Invest Ophthalmol Vis Sci 45:E-Abstract 955.
123. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group. Detection and predictive value of optic disc hemorrhages in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 45:E-Abstract 940.
124. Beiser JA, Hornbeck E, Morrison D, Gordon MO, Goldberg J. De-identification of shared datasets. Clinical Trials 1(1S):274, 2004.
125. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 2449.
126. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW and the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality control in the Ocular Hypertension Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 46: E-Abstract 3738.
127. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA, Gordon MO and the OHTS CSLO Ancillary Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthalmol Vis Sci 46: E-Abstract 3631.
128. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular Hypertension Treatment Study Group. Is there an association of topical ocular hypotensive medication with lens opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 2448.
129. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Alborno MC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Test-retest reproducibility of determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 3630.